

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<u>http://bmjopen.bmj.com</u>).

If you have any questions on BMJ Open's open peer review process please email <u>info.bmjopen@bmj.com</u>

BMJ Open

Protocol for a meta-analysis of recurrence and metastasis of different surgical techniques for early stage non-small cell lung cancer

Journal:	BMJ Open
Manuscript ID	bmjopen-2024-086503
Article Type:	Protocol
Date Submitted by the Author:	16-Mar-2024
Complete List of Authors:	Huang, Xiongfeng; Fuzhou Medical College of Nanchang University Ren, Yuxi; Jiangxi University of Chinese Medicine Cao, Yaoxing; Jiangxi College of Traditional Chinese Medicine Li, Weijuan; Fuzhou Medical College of Nanchang University Lai, Jinxing; Nanchang University Affiliated Ganzhou Hospital
Keywords:	Lung Diseases, ONCOLOGY, SURGERY, Meta-Analysis



1 Protocol for a meta-analysis of recurrence and metastasis of different

2 surgical techniques for early stage non-small cell lung cancer

3 Xiongfeng Huang¹, Yuxi Ren², Yaoxing Cao³, Weijuan Li¹, Jinxing Lai^{4*}

- 1. Fuzhou Medical College of Nanchang University, Fuzhou, China.
- 2. Jiangxi University of Chinese Medicine, Nanchang, China.
- 3. Jiangxi College of Traditional Chinese Medicine, Fuzhou, China.
- 4. Affiliated Ganzhou Hospital of Nanchang University, Ganzhou, China.
- 8 *Correspondence: Jinxing Lai
- 9 *E-mail: laijingxing990@163.com

11 ABSTRACT

12 Introduction

Lung cancer remains the primary cause of cancer-related deaths on a global scale. Surgery is the main therapeutic option for early stage non-small cell lung cancer (NSCLC). However, the optimal surgical approach for lymph node assessment in NSCLC resection remains controversial, and it's still uncertain whether lymph node dissection (LND) is more effective in reducing recurrence and metastasis rates in NSCLC compared to lymph node sampling (LNS). Therefore, we will conduct a meta-analysis to evaluate the recurrence and metastasis of LND versus LNS in patients with early stage NSCLC.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

21 Methods and analysis

This systematic review and meta-analysis will follow the Preferred Reporting Items for Systematic Reviews and Meta-Analysis: The PRISMA Statement. According to the predefined inclusion criteria, we will conduct a comprehensive search for randomized controlled trials (RCTs) and non-randomized studies examining the recurrence and metastasis of LND compared to LNS in patients with stage I-IIIA NSCLC. A literature search from inception in PubMed, EMBASE, the Cochrane Library, CNKI, WanFang, Sinomed, VIP, and Web of Science. There will be no limitations on language, and the search will be undertaken on 1 May 2024 with regular search for new studies.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

BMJ Open

5		
4		
5		
ر م		
6		
7		
Q		
0 0		
9		
1	0	
1	1	
1	n	
!	2	
1	3	
1	4	
1	5	
1	2	
I	6	
1	7	
1	8	
1	õ	
1	9	
2	0	
2	1	
ว	ว	
2 2	2	
2	3	
2	4	
2	5	
- -	6	
2	0	
2	7	
2	8	
2	a	
2 2	2	
3	0	
3	1	
3	2	
с 2	2	
ر د		
3	4	
3	5	
3	6	
- -	-	
3	/	
3	8	
3	9	
Λ	Δ	
-	-	
4	I.	
4	2	
4	3	
^	Δ	
4	4	
4	5	
4	6	
4	7	
^	, 0	
4	0	
4	9	
5	0	
5	1	
, ,	' ~	
5	2	
5	3	
5	4	
5	5	
ر -	2	
5	6	
5	7	
5	8	
כ ר	0	
5	9	

1 2

Additionally, relevant literature references will be retrieved and hand searching of 30 pertinent journals will be conducted. The main outcomes include overall recurrence rate, 31 local recurrence rate, and distant metastasis rate. The supplementary outcomes 32 encompass the rates of regional recurrence and lymph node metastasis. Two 33 independent reviewers will perform screening, data extraction, and quality assessment. 34 Our reviewers will perform subgroup analysis, sensitivity analysis, and publication bias 35 analysis to evaluate the heterogeneity and robustness. Review Manager 5.4 will be 36 applied in analyzing and synthesizing. The Grading of Recommendations Assessment, 37 Development and Evaluation (GRADE) will be used to assess the quality of evidence 38 for the whole study. 39 **Ethics and dissemination** 40

Ethical approval is dispensable for this study since no private information of the
participants will be involved. The findings of the present study will be disseminated
through a peer-reviewed journal or conference presentation.

44 Study registration

45 The protocol of the systematic review has been registered on Open Science Framework,

46 with a registration DOI https://doi.org/10.17605/OSF.IO/S2FT5.

47 STRENGTHS AND LIMITATIONS OF THIS STUDY

- 48 > This protocol adheres to the guidelines established by the Preferred Reporting
 49 Items for Systematic Review and Meta-Analysis Protocols.
- This is a comprehensive review of lymph node dissection versus lymph node
 sampling in early stage non-small cell lung cancer patients.
- To minimize the risk of bias, two researchers will independently carry out the study
 selection, data extraction, and quality assessment.
- The potential existence of significant heterogeneity among various studies could
 hinder the derivation of causal conclusions from their combined findings.

57

58

59 INTRODUCTION

Non-small cell lung cancer (NSCLC), the predominant form of lung malignancy, continues to pose a significant threat to global health. In 2024, the American Cancer Society estimated that lung cancer is the leading cause of cancer death, with an estimated 340 people dying from lung cancer every day, almost 2.5 times more than colorectal cancer, which ranks second in cancer deaths.[1] Lung cancer remains the primary cause of cancer-related deaths on a global scale.[2-5]

Surgical resection plays a crucial role in the management of NSCLC, and lymph node staging is essential for accurate prognostication and treatment planning. Lymph node dissection (LND) and lymph node sampling (LNS) are two surgical techniques used for NSCLC, but their relative effectiveness remains controversial.[6-15] LNS involves the removal of a smaller number of lymph nodes for pathological examination. This approach is generally less invasive, leading to shorter operative times and potentially fewer postoperative complications.[16] However, it may not provide as comprehensive nodal staging as dissection, leading to potential underestimation of the disease stage. LND, conversely, involves the complete removal of lymph nodes and surrounding tissue in specific anatomic regions.[17] This approach offers a comprehensive assessment of nodal involvement, allowing for more accurate staging and potentially improving long-term outcomes. However, it is a more invasive procedure that may increase the risk of post-operative complications, which may result in a reduction in postoperative quality of life for patients. Furthermore, for some patients with early NSCLC, the incidence of lymph node metastasis is not very high, and most patients may not have regional lymph node metastasis. Thus, the necessity of performing complete and systematic lymph node dissection in patients with early-stage NSCLC and whether the expected clinical effect can be achieved remains controversial. Patients with NSCLC continue to experience a notable rate of recurrence and metastasis following surgical intervention, thereby impacting their overall survival outcomes. Several studies have compared the recurrence and metastasis of LND and LNS in NSCLC surgery. Based on three previous studies, [18-20] LND has been shown

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

to reduce the incidence of recurrence and metastasis in early stage NSCLC. And Meng et al.[21] have posited in their meta-analysis that the use of LND may be effective in eliminating hidden micrometastases to reduce the risk of both local recurrence and distant metastases. However, the results of our previous meta-analysis indicated that in individuals with early-stage NSCLC, LND and LNS yielded similar rates of recurrence and metastasis.[22] Additionally, other studies have also shown that lymph node dissection conducted in early-stage lung cancer does not impact the occurrence of recurrence and metastasis.[23-25]

The optimal surgical approach for lymph node assessment in NSCLC resection remains controversial, and it's still uncertain whether LND is more effective in reducing recurrence and metastasis rates in NSCLC compared to LNS. Clearly, newer systematic review and meta-analyses are required to resolve this issue, and definitive analyses can provide stronger rationales for the choice of a specific therapy. Consequently, we will perform a meta-analysis of relevant randomized controlled trials (RCTs) and non-randomized studies to evaluate the recurrence and metastasis of LND versus LNS in early stage NSCLC patients. We hope this meta-analysis will offer strong evidence for the surgical treatment of patients with early stage NSCLC and guide future clinical practice.

5 MATERIALS AND METHODS

Registration and reporting

This review protocol has been officially registered in the Open Science Framework (OSF) database (DOI https://doi.org/10.17605/OSF.IO/S2FT5). And designed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols (PRISMA-P) statement (supplemental File 1).[26] If there is a change to this protocol, details of the amendment and the reasons for it will be added to OSF.

- 114 Eligibility criteria
- **Types of studies**
- 116 All relevant published RCTs and non-randomized studies will be included. The review

will not include certain types of studies, such as methodological papers, editorials,
qualitative research, individual case reports, and secondary studies like narrative
reviews, systematic reviews and meta-analyses. There will be no restrictions on the
language used or the time of publication.

121 Types of participants

Individuals with stage I to IIIA non-small cell lung cancer who received either LND or
LNS will be eligible for inclusion, with no limitations based on country, race, ethnicity,
age, gender, or occupation.

Type of outcomes

The main outcomes are as follows: overall recurrence rate, local recurrence rate (ipsilateral lung, ipsilateral pleura, trachea, etc.), and distant metastasis rate (contralateral lung, contralateral pleura, bone, liver, etc.). The supplementary outcomes encompass the rates of regional recurrence and lymph node metastasis. Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

130 Infor

0 Information source and search strategy

A literature search from inception in PubMed, EMBASE, the Cochrane Library, CNKI, WanFang, Sinomed, VIP, and Web of Science. The Gray Journal includes annual meetings of the American Society of Clinical Oncology and the American Society of Thoracic Surgery (chest surgery), using combinations of the search terms: lymph node dissection, LND, lymph node sampling, LNS, and non-small cell lung cancer, NSCLC. Detailed search strategies are shown in supplemental File 2. There will be no limitations on language, and the search will be undertaken on 1 May 2024 with regular search for new studies. The bibliography of all articles obtained will be examined to identify additional publications that may be pertinent. In addition, abstracts from the American Society of Clinical Oncology and the European Society of Medical Oncology will be searched for potential studies. In order to gather thorough information from qualifying studies, we will contact primary authors to request any pertinent data, such as supplementary materials that may not have been fully disclosed or reported, and information from informal sources related to the research. Two reviewers will examine the reference list and individually choose the studies.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

147 Study Selection

The chosen articles will undergo a dual review process by two separate authors. Following the initial screening of titles and abstracts of papers found through the search strategy, the papers will be sorted into two categories: potentially relevant or not relevant based on the eligibility criteria. Subsequently, efforts will be made to obtain the full texts of all potentially relevant papers, which will then be reviewed against the eligibility criteria. In the event of disagreements during the full-text screening, they will be resolved through discussion. If a consensus cannot be reached, a third author will step in to settle the dispute. The study selection process is illustrated in Figure 1.

Data extraction process

The data will be taken from each full-text article that meets the eligibility criteria: study design; country of study; interventions; outcomes; number and general characteristics of participants, for example, age, and gender. If data is missing, we will reach out to the original author to request additional information. The process of data extraction will be conducted by two reviewers, with Microsoft Excel being employed as the tool for data collection. Any disagreements between the two reviewers will be resolved by discussion or by consulting with the third reviewer, the characteristics of the study are attached as Supplemental File 3.

Study risk of bias assessment

166 Two reviewers will assess the quality of the included studies. Disagreement between167 the two reviewers will be resolved by discussion with the third reviewer.

We will evaluate the included RCTs' quality using the Cochrane Handbook's "risk of bias" technique.[27] Sequence generation, allocation concealment, blinding, incomplete data, and selective reporting were assessed, and each of them was graded as "yes(+)", "no(-)" or "unclear(?)", which reflected low risk of bias, high risk of bias, and uncertain risk of bias, respectively.[28] The Newcastle-Ottawa scale will be used to evaluate the methodological rigor of non-randomized studies. The Newcastle-Ottawa Scale consists of eight items that are divided into three categories: selection (four items, one star each), comparability (one item, up to two stars), and exposure/outcome (three items, one star each).[29] One star will be given for each item in the selection and

Page 7 of 22

BMJ Open

outcome domains, and up to two stars will be given for the comparability domain, when
a primary study satisfies the methodological required standard. Studies with star values
between 0 and 4 will ultimately be classified as having a high risk of bias, studies with
scores between 5 and 6 as having a moderate risk of bias, and studies with scores
between 7 and 9 as having a low risk of bias.[30]

182 DATA ANALYSIS

183 Statistical analysis

Meta-analysis will be planned with sufficient clinically and statistically homogeneous and comparable reported outcomes among studies by pooling data using Review Manager V.5.4 software by The Cochrane Collaboration. Dichotomous data will be compared using a risk ratio (RR) or odds ratio (OR). Respective 95% confidence intervals (CI) will be calculated for each estimate and presented in forest plots. Statistical heterogeneity will be assessed visually by Q and I^2 statistics.[31] For the Q statistic, a *P* value<0.10 Will be regarded as statistically significant for heterogeneity. For the I^2 statistic, [32] if there is heterogeneity among the study results ($I^2 > 50\%$), the heterogeneity source will be further examined. After the exclusion of effects exerted by significant clinical heterogeneity, the random-effects model will be employed for the meta-analysis. [33 34] If there is no heterogeneity between the study results ($I^{2} < 50\%$), this study will use the fixed-effect model in terms of meta-analysis.[35 36] All reported *P*-values are 2-sided and values of P < 0.05 will be regarded as significant for all included studies. A narrative synthesis will be carried out if insufficient homogeneous studies make meta-analysis impractical.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

Assessment of publication bias

The funnel plot will be used to assess reporting bias. A symmetrical funnel shape will suggest the absence of publication bias, whereas an asymmetrical funnel plot will indicate the presence of such bias. An objective assessment of publication bias will be conducted employing Egger's linear regression test, where a p-value less than 0.1 is considered statistically significant, indicating the presence of publication bias.[37 38]

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Subgroup and sensitivity analyses

Subgroup analyses will be conducted based on study and population variables, including age, gender, intervention approaches, sample size, and other factors. For sensitivity analysis, studies of poorer methodological quality will be removed to see if their deletion alters the outcomes of the analyses. When heterogeneity is substantial, the leave-one-out method is employed to ascertain whether it arises from a specific study. For instance, to ascertain whether heterogeneity diminishes, we eliminate one study. This approach is employed to investigate each study individually, in order to identify the root cause of heterogeneity.

Grading the quality of evidence

The evaluation of the evidence's quality throughout the entire study will be conducted utilizing the GRADE (Grading of Recommendations Assessment, Development and Evaluation) framework.[39-41] This system is frequently employed to evaluate the credibility of evidence and determine the level of recommendations. Two independent reviewers will employ the five GRADE considerations, including the risk of bias, consistency of effect, imprecision, indirectness, and publication bias, to meticulously evaluate the certainty of the evidence and arrive at sound conclusions. [42 43]

Updates to study protocol

If modifications to the review protocol are deemed necessary, these adjustments will be thoroughly documented and incorporated as supplementary material alongside the final manuscript. Additionally, these updates will be reflected on the OSF register for future reference.

Patient and public involvement

We do not have any intention to involve patients or the general public in the planning,

- execution, reporting, or dissemination of our systematic review.
- **Ethics and dissemination**

Ethical approval is dispensable for this study since no private information of the participants will be involved. The findings of the present study will be disseminated through a peer-reviewed journal or conference presentation.

1	
2	
3	
4	
5	
6	
7	
, Q	
0	
9	
10	
11	
12	
13	
14	
15	
16	
17	
10	
10	
19	
20	
21	
22	
23	
24	
25	
26	
20	
27	
28	
29	
30	
31	
32	
33	
34	
35	
26	
20	
37	
38	
39	
40	
41	
42	
43	
44	
77 45	
43	
46	
47	
48	
49	
50	
51	
52	
52	
55	
אנ רי	
55	
56	
57	
58	
59	
60	

236 Author contributions

XH conceived the study. XH and YC registered the protocol. XH and WL drafted the
protocol. YC and JL revised it. XH and YR developed the search strategies and will run
them. JL and YC will select studies and extract data. XH will analyze the data. All
authors contributed to the article and approved the submitted version.

241 Funding

This study was supported by the Jiangxi Province key research and development
program (No.2020YBBGWL001); and the Jiangxi Provincial Department of Education
Science and Technology research key project (No.GJJ208902).

245 **Competing interests**

246 The authors declare no conflict of interest.

247 Word count

248 2072 words

249

250 **REFERENCES**

251 1. Siegel RL, Giaquinto AN. Cancer statistics, 2024. 2024;74(1):12-49. doi: 10.3322/caac.21820

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

- 252 2. Bade BC, Dela Cruz CS. Lung Cancer 2020: Epidemiology, Etiology, and Prevention. *Clinics in* 253 *chest medicine* 2020;41(1):1-24. doi: 10.1016/j.ccm.2019.10.001 [published Online First:
 254 2020/02/06]
- 3. Herbst RS, Heymach JV, Lippman SM. Lung cancer. *The New England journal of medicine*2008;359(13):1367-80. doi: 10.1056/NEJMra0802714 [published Online First: 2008/09/26]
- 4. Gridelli C, Rossi A, Maione P, et al. Vaccines for the treatment of non-small cell lung cancer: a
 renewed anticancer strategy. *The oncologist* 2009;14(9):909-20. doi:
 10.1634/theoncologist.2009-0017 [published Online First: 2009/09/04]
- 5. Jemal A, Bray F, Center MM, et al. Global cancer statistics. *CA: a cancer journal for clinicians*2011;61(2):69-90. doi: 10.3322/caac.20107 [published Online First: 2011/02/08]
- 262 6. Xu J, Lai J, Huang X. Survival outcomes following complete mediastinal lymphadenectomy or
 263 selective mediastinal lymphadenectomy in patients with stage I-IIIA non-small cell lung cancer:
 264 protocol for a systematic review and meta-analysis. 2024;14(3):e084520. doi:

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

BMJ Open

2
4
5
6
7
8
9
10
11
11
12
13
14
15
16
17
18
19
20
20 21
21
22
23
24
25
26
27
27
20
29
30
31
32
33
34
35
36
20
3/
38
39
40
41
42
43
44
45
45 46
40
4/
48
49
50
51
52
53
57
54 FF
22
56
57
58
59
60

1 2

> 265 10.1136/bmjopen-2024-084520

7. Zhang Y, Deng C, Zheng Q, et al. Selective Mediastinal Lymph Node Dissection Strategy for 266 267 Clinical T1N0 Invasive Lung Cancer: A Prospective, Multicenter, Clinical Trial. Journal of 268 thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2023;18(7):931-39. doi: 10.1016/j.jtho.2023.02.010 [published Online First: 269 270 2023/02/26]

- 271 8. Wang Y, Darling GE. Complete mediastinal lymph node dissection versus systematic lymph node 272 sampling in surgical treatment of non-small cell lung cancer: do we have the answer? Journal of thoracic disease 2017;9(11):4169-70. doi: 10.21037/jtd.2017.10.39 [published Online First: 273 274 2017/12/23]
- 275 9. Xu F, Qi L, Yue D, et al. The effect of the extent of lymph node dissection for stage IA non-276 small-cell lung cancer on patient disease-free survival. Clinical lung cancer 2013;14(2):181-7. 277 doi: 10.1016/j.cllc.2012.09.002 [published Online First: 2012/12/01]
- 278 10. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in medicine 1998;17(24):2815-34. doi: 279 280 10.1002/(sici)1097-0258(19981230)17:24<2815::aid-sim110>3.0.co;2-8 [published Online 281 First: 1999/01/28]
- 282 11. Ou SH, Zell JA. Prognostic significance of the number of lymph nodes removed at lobectomy 283 in stage IA non-small cell lung cancer. Journal of thoracic oncology : official publication of the 284 International Association for the Study of Lung Cancer 2008;3(8):880-6. doi: 285 10.1097/JTO.0b013e31817dfced [published Online First: 2008/08/02]
- 286 12. Wang Z, Qi Z, Cheng D, et al. Lobe-Specific Node Dissection Can Be a Suitable Alternative to 287 Systematic Lymph Node Dissection in Highly Selective Early-Stage Non-Small-Cell Lung 288 Cancer Patients: A Meta-Analysis. Annals of thoracic and cardiovascular surgery : official 289 journal of the Association of Thoracic and Cardiovascular Surgeons of Asia 2021;27(3):143-290 50. doi: 10.5761/atcs.oa.20-00136 [published Online First: 2020/12/08]
 - 291 13. Tantraworasin A, Saeteng S, Siwachat S, et al. Impact of lymph node management on resectable 292 non-small cell lung cancer patients. Journal of thoracic disease 2017;9(3):666-74. doi: 293 10.21037/jtd.2017.02.90 [published Online First: 2017/04/30]
 - 294 14. Yang M, Cao H, Guo X, et al. The number of resected lymph nodes (nLNs) combined with 10

י ר	
2 3	
4	
5	
6	
7	
8	
9	
10	
11	
12	
13	
14	
15	
17	
18	
19	
20	
21	
22	
23	
24	
25	
26	
27	
20 29	
30	
31	
32	
33	
34	
35	
36	
3/	
38 20	
40	
41	
42	
43	
44	
45	
46	
47	
48	
49 50	
5U 51	
57	
53	
54	
55	
56	
57	
58	
59	
60	

tumor size as a prognostic factor in patients with pathologic N0 and Nx non-small cell lung
cancer. *PloS one* 2013;8(9):e73220. doi: 10.1371/journal.pone.0073220 [published Online First:
2013/09/12]

15. Wang W, Chen D, Xi K, et al. Impact of Different Types of Lymphadenectomy Combined With
Different Extents of Tumor Resection on Survival Outcomes of Stage I Non-small-cell Lung
Cancer: A Large-Cohort Real-World Study. *Frontiers in oncology* 2019;9:642. doi:
10.3389/fonc.2019.00642 [published Online First: 2019/08/10]

- 302 16. Dezube AR, Mazzola E, Bravo-Iñiguez CE, et al. Analysis of Lymph Node Sampling Minimums
 303 in Early Stage Non-Small-Cell Lung Cancer. *Seminars in thoracic and cardiovascular surgery* 304 2021;33(3):834-45. doi: 10.1053/j.semtcvs.2020.11.007 [published Online First: 2020/11/13]
- 305 17. Kim K. Video-Assisted Thoracic Surgery Mediastinal Lymph Node Dissection in Lung Cancer
 306 Surgery. *Journal of chest surgery* 2021;54(4):258-62. doi: 10.5090/jcs.21.054 [published Online
 307 First: 2021/08/07]
 - 308 18. Wu Y, Huang ZF, Wang SY, et al. A randomized trial of systematic nodal dissection in
 309 resectable non-small cell lung cancer. *Lung cancer (Amsterdam, Netherlands)* 2002;36(1):1-6.
 310 doi: 10.1016/s0169-5002(01)00445-7 [published Online First: 2002/03/14]
- 311 19. Su X, Wang X, Long H, et al. Mediastinal lymph node dissection affects survival in patients
 312 with stage I non-small cell lung cancer. *The Thoracic and cardiovascular surgeon*313 2008;56(4):226-30. doi: 10.1055/s-2007-989494 [published Online First: 2008/05/16]
- 20. Lardinois D, Suter H, Hakki H, et al. Morbidity, survival, and site of recurrence after mediastinal
 lymph-node dissection versus systematic sampling after complete resection for non-small cell
 lung cancer. *The Annals of thoracic surgery* 2005;80(1):268-74; discussion 74-5. doi:
 10.1016/j.athoracsur.2005.02.005 [published Online First: 2005/06/25]
- 318 21. Meng D, Zhou Z, Wang Y, et al. Lymphadenectomy for clinical early-stage non-small-cell lung
 319 cancer: a systematic review and meta-analysis. *European journal of cardio-thoracic surgery :*
- 320 official journal of the European Association for Cardio-thoracic Surgery 2016;50(4):597-604.
 - doi: 10.1093/ejcts/ezw083 [published Online First: 2016/04/24]

322 22. Huang X, Wang J, Chen Q, et al. Mediastinal lymph node dissection versus mediastinal lymph

node sampling for early stage non-small cell lung cancer: a systematic review and meta-analysis.

⁰ 324 *PloS one* 2014;9(10):e109979. doi: 10.1371/journal.pone.0109979 [published Online First:

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

325 2014/10/09]

326 23. Mokhles S, Macbeth F, Treasure T, et al. Systematic lymphadenectomy versus sampling of
327 ipsilateral mediastinal lymph-nodes during lobectomy for non-small-cell lung cancer: a
328 systematic review of randomized trials and a meta-analysis. *European journal of cardio-*329 *thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery*

330 2017;51(6):1149-56. doi: 10.1093/ejcts/ezw439 [published Online First: 2017/02/06]

- 24. Luo J, Yang S, Dong S. Selective Mediastinal Lymphadenectomy or Complete Mediastinal
 Lymphadenectomy for Clinical Stage I Non-Small Cell Lung Cancer: A Meta-Analysis.
 2021;38(12):5671-83. doi: 10.1007/s12325-021-01954-w
- 25. Darling GE, Allen MS, Decker PA, et al. Randomized trial of mediastinal lymph node sampling
 versus complete lymphadenectomy during pulmonary resection in the patient with N0 or N1
- 336 (less than hilar) non-small cell carcinoma: results of the American College of Surgery Oncology
- Group Z0030 Trial. *The Journal of thoracic and cardiovascular surgery* 2011;141(3):662-70.

doi: 10.1016/j.jtcvs.2010.11.008 [published Online First: 2011/02/22]

- 26. Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and
 meta-analysis protocols (PRISMA-P) 2015 statement. *Systematic reviews* 2015;4(1):1. doi:
 10.1186/2046-4053-4-1 [published Online First: 2015/01/03]
- 342 27. Higgins JP, Thomas J, Chandler J, et al. Cochrane Handbook for Systematic Reviews of
 343 Interventions version 6.4 (updated August 2023). *Cochrane* 2023
- 344 28. Higgins JP, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration's tool for assessing
 345 risk of bias in randomised trials. *BMJ (Clinical research ed)* 2011;343:d5928. doi:
 346 10.1136/bmj.d5928 [published Online First: 2011/10/20]
- 347 29. Wells G, Shea B, O'Connell D, et al. The newcastle-ottawa scale(NOS) for assessing the quality
 348 of nonrandomised studies in meta-analyses. 2020
- 349 30. Luchini C, Stubbs B, Solmi M, et al. Assessing the quality of studies in meta-analyses:
 350 Advantages and limitations of the Newcastle Ottawa Scale. *World J Meta-Anal* 2017(4):80-84.
- 351 31. Peters JL, Sutton AJ, Jones DR, et al. Comparison of two methods to detect publication bias in
 352 meta-analysis. *Jama* 2006;295(6):676-80. doi: 10.1001/jama.295.6.676 [published Online First:
 353 2006/02/10]
 - 354 32. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. *BMJ* 12

BMJ Open

2		
3	355	(Clinical research ed) 2003;327(7414):557-60. doi: 10.1136/bmj.327.7414.557 [published
5 6	356	Online First: 2003/09/06]
7 8	357	33. DerSimonian R, Laird N. Meta-analysis in clinical trials revisited. Contemporary clinical trials
9 10	358	2015;45(Pt A):139-45. doi: 10.1016/j.cct.2015.09.002 [published Online First: 2015/09/08]
11 12	359	34. DerSimonian R, Kacker R. Random-effects model for meta-analysis of clinical trials: an update.
13 14	360	Contemporary clinical trials 2007;28(2):105-14. doi: 10.1016/j.cct.2006.04.004 [published
15 16	361	Online First: 2006/06/30]
17 18	362	35. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Statistics in medicine
19 20	363	2002;21(11):1539-58. doi: 10.1002/sim.1186 [published Online First: 2002/07/12]
21 22	364	36. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of
23 24	365	disease. Journal of the National Cancer Institute 1959;22(4):719-48. [published Online First:
25	366	1959/04/01]
27	367	37. Cumpston MS, McKenzie JE, Welch VA, et al. Strengthening systematic reviews in public
29	368	health: guidance in the Cochrane Handbook for Systematic Reviews of Interventions, 2nd
31 22	369	edition. Journal of public health (Oxford, England) 2022;44(4):e588-e92. doi:
33 34	370	10.1093/pubmed/fdac036 [published Online First: 2022/03/31]
35 26	371	38. Sterne JA, Egger M, Smith GD. Systematic reviews in health care: Investigating and dealing
36 37	372	with publication and other biases in meta-analysis. BMJ (Clinical research ed)
38 39	373	2001;323(7304):101-5. doi: 10.1136/bmj.323.7304.101 [published Online First: 2001/07/14]
40 41	374	39. Langer G, Meerpohl JJ, Perleth M, et al. [GRADE guidelines: 12. Developing Summary of
42 43	375	Findings tables - dichotomous outcomes]. Zeitschrift fur Evidenz, Fortbildung und Qualitat im
44 45	376	Gesundheitswesen 2013;107(9-10):646-64. doi: 10.1016/j.zefq.2013.10.034 [published Online
46 47	377	First: 2013/12/10]
48 49	378	40. Guyatt GH, Oxman AD, Kunz R, et al. What is "quality of evidence" and why is it important to
50 51	379	clinicians? BMJ (Clinical research ed) 2008;336(7651):995-8. doi:
52 53	380	10.1136/bmj.39490.551019.BE [published Online First: 2008/05/06]
54 55	381	41. Guyatt GH, Oxman AD, Kunz R, et al. GRADE guidelines: 2. Framing the question and deciding
56 57	382	on important outcomes. Journal of clinical epidemiology 2011;64(4):395-400. doi:
58 59	383	10.1016/j.jclinepi.2010.09.012 [published Online First: 2011/01/05]
60	384	42. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of

evidence and strength of recommendations. BMJ (Clinical research ed) 2008;336(7650):924-6.
doi: 10.1136/bmj.39489.470347.AD [published Online First: 2008/04/26]
43. H S, Brozek J, Oxman AE. GRADE handbook for grading quality of evidence and strength of
recommendation. 2009
Appendices
Fig 1. Flow diagram showing the selection process of articles.
Supplemental File 1. PRISMA-P-checklist.
Supplemental File 2. Search strategy.
Supplemental File 3. General information of the included studies.

PRISMA 2020 flow diagram for new systematic reviews which included searches of databases and registers only



PRISMA-P (Pref address in a syste	ferrec emati	ا Reporting Items for Systematic review and Meta-Analysis Protocols) 2015 check i Reporting Items for Systematic review and Meta-Analysis Protocols) 2015 check c review protocol*	tems to
Section and topic	Item No	Checklist item of 2 Emet	Reported on Page #
ADMINISTRATIVI	E INF(DRMATION SSE	
Title:		agne 202	
Identification	1a	Identify the report as a protocol of a systematic review	P1
Update	1b	If the protocol is for an update of a previous systematic review, identify as such	N/A
Registration	2	If registered, provide the name of the registry (such as PROSPERO) and registration number	P2
Authors:		and	
Contact	3a	Provide name, institutional affiliation, e-mail address of all protocol authors; provide physical mathematical address of corresponding author	P1
Contributions	3b	Describe contributions of protocol authors and identify the guarantor of the review	P9
Amendments	4	If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments	N/A
Support:			
Sources	5a	Indicate sources of financial or other support for the review	N/A
Sponsor	5b	Provide name for the review funder and/or sponsor	N/A
Role of sponsor or funder	5c	Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol	N/A
INTRODUCTION			
Rationale	6	Describe the rationale for the review in the context of what is already known	P3-4
Objectives	7	Provide an explicit statement of the question(s) the review will address with reference to participants, metrventions, comparators, and outcomes (PICO)	P4-5
METHODS		gies	
Eligibility criteria	8	Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as years considered, language, publication status) to be used as criteria for eligibility for the review	P4-5
Information sources	9	Describe all intended information sources (such as electronic databases, contact with study authors, trail registers or other grey literature sources) with planned dates of coverage	P5
Search strategy	10	Present draft of search strategy to be used for at least one electronic database, including planned limit such that it could be repeated	P5
		phique de de	

2		BMJ Open Copyr	
		ight, i	
Study records:			
Data management	11a	Describe the mechanism(s) that will be used to manage records and data throughout the review $\begin{bmatrix} a & b \\ c & b \\ c & c \\ c & c$	P6
Selection process	11b	State the process that will be used for selecting studies (such as two independent reviewers) through each phase of the review (that is, screening, eligibility and inclusion in meta-analysis)	P6
Data collection process	n 11c	Describe planned method of extracting data from reports (such as piloting forms, done independent in the processes for obtaining and confirming data from investigators	P6
Data items	12	List and define all variables for which data will be sought (such as PICO items, funding sources) and simplifications	P6
Outcomes and prioritization	13	List and define all outcomes for which data will be sought, including prioritization of main and a definitional and a definition of main and a def	P5
Risk of bias in individual studies	14	Describe anticipated methods for assessing risk of bias of individual studies, including whether the savel be done at the outcome or study level, or both; state how this information will be used in data synthesis	P6-7
Data synthesis	15a	Describe criteria under which study data will be quantitatively synthesised	P7
	15b	If data are appropriate for quantitative synthesis, describe planned summary measures, methods a formation of combining data from studies, including any planned exploration of consistency (such as I ² , Kendal's s)	f P7
	15c	Describe any proposed additional analyses (such as sensitivity or subgroup analyses, meta-regrestion)	P8
	15d	If quantitative synthesis is not appropriate, describe the type of summary planned	P7
Meta-bias(es)	16	Specify any planned assessment of meta-bias(es) (such as publication bias across studies, selective reporting within studies)	P7
Confidence in cumulative evidence	17 ce	Describe how the strength of the body of evidence will be assessed (such as GRADE)	P8
From: Shamseer L, meta-analysis prote	e items. A p and is c Moher I pcols (PR	Amendments to a review protocol should be tracked and dated. The copyright for PRISMA-P (including checklist) is held listributed under a Creative Commons Attribution Licence 4.0. D, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart L, PRISMA-P Group. Preferred reporting items for systemat (ISMA-P) 2015: elaboration and explanation. BMJ. 2015 Jan 2;349(jan02 1):g7647.	by the
		es. Ager	
		Ce Bit	
		sliogr	
		dt Alexander Ale	
		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Supplementary file 2. Search strategy

1. PubMed

Number	Search terms					
#1	Non-Small-Cell OR Non-Small-Cell Lung Carcinomas OR Non-Small					
	Cell Lung Cancer OR Non-Small-Cell Lung Carcinoma OR Non-Small					
	Cell Lung Carcinoma OR Non-Small Cell Lung OR Non-Small Cell Lung					
	Cancer OR Lung Neoplasms OR Pulmonary Neoplasms OR Lung					
	Neoplasm OR Pulmonary Neoplasm OR Lung Cancer OR Lung Cancers					
	OR Pulmonary Cancer OR Pulmonary Cancers OR Cancer of the Lung					
	OR Cancer of Lung OR Non-Small-Cell Lung OR Lung Carcinoma OR					
	Non-Small-Cell OR Lung Carcinomas OR NSCLC [Title/Abstract]					
#2	Surgical Procedures OR Operative OR surgery OR surgery OR surgical					
	OR operative OR postoperative [Title/Abstract]					
#3	lymphadenectomy OR lymphadenectomy OR complete mediastinal					
	lymphadenectomy OR mediastinal lymph node excision OR lobe-specific					
	lymph node dissection OR mediastinal lymph node dissection OR					
	mediastinal lymph node sampling OR lymph node dissection OR lymph					
	node OR dissect OR sample OR selective mediastinal lymphadenectomy					
	OR systematic lymph node dissection OR selective lymph node dissection					
	OR LND OR LNS [Title/Abstract]					
#4	randomly OR randomized OR RCT OR trials OR cohort OR longitudinal					
	OR prospective OR survival [Title/Abstract]					
#5	#1 AND #2 AND #3 AND #4 [Title/Abstract]					
2. Embas	e O					

2. Embase

Number	Search terms				
#1	Non-Small-Cell:ti,ab,kw OR Non-Small-Cell Lung Carcinomas:ti,ab,kw				
	OR Non-Small Cell Lung Cancer:ti,ab,kw OR Non-Small-Cell Lung				
	Carcinoma:ti,ab,kw OR Non-Small Cell Lung Carcinoma:ti,ab,kw OR				
	Non-Small Cell Lung:ti,ab,kw OR Non-Small Cell Lung Cancer:ti,ab,kw				
	OR Lung Neoplasms:ti,ab,kw OR Pulmonary Neoplasms:ti,ab,kw OR				
	Lung Neoplasm:ti,ab,kw OR Pulmonary Neoplasm:ti,ab,kw OR Lung				
	Cancer:ti,ab,kw OR Lung Cancers:ti,ab,kw OR Pulmonary				
	Cancer:ti,ab,kw OR Pulmonary Cancers:ti,ab,kw OR Cancer of the				
	Lung:ti,ab,kw OR Cancer of Lung:ti,ab,kw OR Non-Small-Cell				
	Lung:ti,ab,kw OR Lung Carcinoma:ti,ab,kw OR Non-Small-Cell:ti,ab,kw				
	OR Lung Carcinomas:ti,ab,kw OR NSCLC:ti,ab,kw				
#2	Surgical Procedures:ti,ab,kw OR Operative OR surgery:ti,ab,kw OR				
	surgery:ti,ab,kw OR surgical:ti,ab,kw OR operative:ti,ab,kw OR				
	postoperative:ti,ab,kw				

1	
2	
3	
4	
5	
0	
, 8	
9	
10	
11	
12	
13	
14	
15	
17	
18	
19	
20	
21	
22	
23	
24	
26	
27	
28	
29	
30	
31	
33	
34	
35	
36	
37	
38	
39 40	
40	
42	
43	
44	
45	
46	
47 78	
40 49	
50	
51	
52	
53	
54	
55	
56 57	
57 58	
59	

#3	lymphadenectomy:ti,ab,kw OR lymphadenectomy:ti,ab,kw OR complete
	mediastinal lymphadenectomy:ti,ab,kw OR mediastinal lymph node
	excision:ti,ab,kw OR lobe-specific lymph node dissection:ti,ab,kw OR
	mediastinal lymph node dissection:ti,ab,kw OR mediastinal lymph node
	sampling:ti,ab,kw OR lymph node dissection:ti,ab,kw OR lymph
	node:ti,ab,kw OR dissect:ti,ab,kw OR sample:ti,ab,kw OR selective
	mediastinal lymphadenectomy:ti,ab,kw OR systematic lymph node
	dissection:ti,ab,kw OR selective lymph node dissection:ti,ab,kw OR
	LND:ti,ab,kw OR LNS:ti,ab,kw
#4	randomly:ti,ab,kw OR randomized:ti,ab,kw OR RCT:ti,ab,kw OR
	trials:ti,ab,kw OR cohort:ti,ab,kw OR longitudinal:ti,ab,kw OR
	prospective:ti,ab,kw OR survival:ti,ab,kw
#5	#1 AND #2 AND #3 AND #4

3. Cochrane Library

Number	Search terms				
#1	1 Non-Small-Cell:ti,ab,kw OR Non-Small-Cell Lung Carcinomas:ti,				
	OR Non-Small Cell Lung Cancer:ti,ab,kw OR Non-Small-Cell Lung				
	Carcinoma:ti,ab,kw OR Non-Small Cell Lung Carcinoma:ti,ab,kw OR				
	Non-Small Cell Lung:ti,ab,kw OR Non-Small Cell Lung Cancer:ti,ab,				
	OR Lung Neoplasms:ti,ab,kw OR Pulmonary Neoplasms:ti,ab,kw O				
	Lung Neoplasm:ti,ab,kw OR Pulmonary Neoplasm:ti,ab,kw OR I				
	Cancer:ti,ab,kw OR Lung Cancers:ti,ab,kw OR Pulmonary				
	Cancer:ti,ab,kw OR Pulmonary Cancers:ti,ab,kw OR Cancer of the				
	Lung:ti,ab,kw OR Cancer of Lung:ti,ab,kw OR Non-Small-Cell				
	Lung:ti,ab,kw OR Lung Carcinoma:ti,ab,kw OR Non-Small-Cell:ti,ab,kw				
	OR Lung Carcinomas:ti,ab,kw OR NSCLC:ti,ab,kw				
#2	Surgical Procedures:ti,ab,kw OR Operative OR surgery:ti,ab,kw OR				
	surgery:ti,ab,kw OR surgical:ti,ab,kw OR operative:ti,ab,kw OR				
	postoperative:ti,ab,kw				
#3	lymphadenectomy:ti,ab,kw OR lymphadenectomy:ti,ab,kw OR complete				
	mediastinal lymphadenectomy:ti,ab,kw OR mediastinal lymph node				
	excision:ti,ab,kw OR lobe-specific lymph node dissection:ti,ab,kw OR				
	mediastinal lymph node dissection:ti,ab,kw OR mediastinal lymph node				
	sampling:ti,ab,kw OR lymph node dissection:ti,ab,kw OR lymph				
	node:ti,ab,kw OR dissect:ti,ab,kw OR sample:ti,ab,kw OR selective				
	mediastinal lymphadenectomy:ti,ab,kw OR systematic lymph node				
	dissection:ti,ab,kw OR selective lymph node dissection:ti,ab,kw OR				
	LND:ti,ab,kw OR LNS:ti,ab,kw				
#4	randomly:ti,ab,kw OR randomized:ti,ab,kw OR RCT:ti,ab,kw OR				
	trials:ti,ab,kw OR cohort:ti,ab,kw OR longitudinal:ti,ab,kw OR				
	prospective:ti,ab,kw OR survival:ti,ab,kw				

#5	#1 AND #2 AND #3 AND #4

4. Web of Science

Number	Search terms	
#1	TS=(Non-Small-Cell OR Non-Small-Cell Lung Carcinomas OR Non-	
	Small Cell Lung Cancer OR Non-Small-Cell Lung Carcinoma OR Non-	
	Small Cell Lung Carcinoma OR Non-Small Cell Lung OR Non-Small Cell	
	Lung Cancer OR Lung Neoplasms OR Pulmonary Neoplasms OR Lung	
	Neoplasm OR Pulmonary Neoplasm OR Lung Cancer OR Lung Cancers	
	OR Pulmonary Cancer OR Pulmonary Cancers OR Cancer of the Lung	
	OR Cancer of Lung OR Non-Small-Cell Lung OR Lung Carcinoma OR	
	Non-Small-Cell OR Lung Carcinomas OR NSCLC)	
#2	TS=(Surgical Procedures OR Operative OR surgery OR surgery	
	surgical OR operative OR postoperative)	
#3	TS=(lymphadenectomy OR lymphadenectomy OR complete mediastir	
	lymphadenectomy OR mediastinal lymph node excision OR lobe-specific	
	lymph node dissection OR mediastinal lymph node dissection OR	
	mediastinal lymph node sampling OR lymph node dissection OR lymph	
	node OR dissect OR sample OR selective mediastinal lymphadenectomy	
	OR systematic lymph node dissection OR selective lymph node dissection	
	OR LND OR LNS)	
#4	TS=(randomly OR randomized OR RCT OR trials OR cohort OR	
	longitudinal OR prospective OR survival)	
#5	#1 AND #2 AND #3 AND #4	

5. China National Knowledge Infrastructure (CNKI) (Chinese)

Search terms
(主题:"非小细胞肺癌" or "肺癌") and (主题:"淋巴结清扫方式" or "系统性
淋巴结清扫" or "选择性淋巴结清扫" or "叶特异性淋巴结清扫" or "纵膈淋巴
结清扫" or "纵膈淋巴结采样") and (全部: "随机对照试验")

6. WANFANG DATA (Chinese)

Search terms				
(主题:"非小细胞肺癌" or "肺癌") and (主题:"淋巴结清扫方式" or "系统性				
淋巴结清扫" or "选择性淋巴结清扫" or "叶特异性淋巴结清扫" or "纵膈淋巴				
结清扫" or "纵膈淋巴结采样") and (全部: "随机对照试验")				

3	
1	
4	
5	
6	
7	
8	
9	
10	
11	
11	
12	
13	
14	
15	
16	
17	
10	
10	
19	
20	
21	
22	
23	
20	
24	
25	
26	
27	
28	
29	
30	
21	
51	
- 32	
33	
33 34	
33 34 35	
33 34 35 36	
33 34 35 36	
33 34 35 36 37	
33 34 35 36 37 38	
33 34 35 36 37 38 39	
33 34 35 36 37 38 39 40	
33 34 35 36 37 38 39 40 41	
33 34 35 36 37 38 39 40 41 42	
 33 34 35 36 37 38 39 40 41 42 43 	
 33 34 35 36 37 38 39 40 41 42 43 	
 33 34 35 36 37 38 39 40 41 42 43 44 	
 33 34 35 36 37 38 39 40 41 42 43 44 45 	
 33 34 35 36 37 38 39 40 41 42 43 44 45 46 	
33 34 35 36 37 38 39 40 41 42 43 44 45 46 47	
33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48	
 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 	
 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 	
 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 50 	
 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 	
 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 	
33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53	
33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54	
33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55	
33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56	
33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56	
33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 7	
 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 	
33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59	

7. Chinese biomedical literature service system (Sinomed) (Chinese)

Search terms				
("非小细胞肺癌" [常用字段:智能] OR "肺癌" [常用字段:智能]) AND ("肺癌"[常				
用字段:智能]) AND ("随机对照试验"[常用字段:智能]) AND ("淋巴结清扫方式				
"[全部字段:智能] OR "系统性淋巴结清扫"[全部字段:智能]OR "选择性淋巴结				
清扫"[全部字段:智能] OR "叶特异性淋巴结清扫"[全部字段:智能] OR "纵膈淋				
巴结采样"[全部字段:智能])				

8. VIP database (Chinese)

Search terms			
(主题:"非小细胞肺癌" or "肺癌") and (主题:"淋巴结清扫方式" or "系统性			
淋巴结清扫" or "选择性淋巴结清扫" or "叶特异性淋巴结清扫" or "纵膈淋巴			
结清扫" or "纵膈淋巴结采样") and (全部: "随机对照试验")			

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

1	
2	
3	
Δ	
5	
د د	
0	
/	
8	
9	
10	
11	
12	
13	
14	
15	
16	
17	
12	
10	
יק רכ	
20 21	
21	
22	
23	
24	
25	
26	
27	
28	
29	
30	
31	
32	
33	
37	
25	
22	
30	
37	
38	
39	
40	
41	
42	
43	
44	
45	
46	
47	
48	
49	
50	
50	
57	
52 53	
55 54	
54	
55	
56	
57	
58	
59	

	1	
First author		
Country, year		
Sample size (males/females)		
Median age, y (range)		
Design		
Include or exclude		
Reason(s) for exclusion		
Follow-up (mean and range) (months)		
Tumor location		
Tumor size(cm)		
Tumor stage		
Surgery procedure		
Adjuvant treatment		
Primary outcomes:		
1. Overall recurrence rate		
2. Local recurrence rate (ipsilateral		
lung, ipsilateral pleura, trachea, etc.)		
3. Distant metastasis rate (contralateral		
lung, contralateral pleura, bone, liver, etc.)		
Second outcomes:		
1. Regional recurrence rate		
2. Lymph node metastasis rate		

BMJ Open

Protocol for a systematic review and meta-analysis of recurrence and metastasis of different surgical techniques for non-small cell lung cancer

Journal:	BMJ Open
Manuscript ID	bmjopen-2024-086503.R1
Article Type:	Protocol
Date Submitted by the Author:	26-Jul-2024
Complete List of Authors:	Huang, Xiongfeng; Fuzhou Medical College, Nanchang University Zhu, Donghong; The Ninth Hospital of Nanchang, Department of Respiratory Cao, Yaoxing; Jiangxi College of Traditional Chinese Medicine Li, Weijuan; Fuzhou Medical College, Nanchang University Lai, Jinxing; Affiliated Ganzhou Hospital of Nanchang University Ren, Yuxi; Jiangxi University of Traditional Chinese Medicine
Primary Subject Heading :	Surgery
Secondary Subject Heading:	Oncology
Keywords:	Lung Diseases, ONCOLOGY, SURGERY, Meta-Analysis



2

3

cancer

BMJ Open

Protocol for a systematic review and meta-analysis of recurrence and

metastasis of different surgical techniques for non-small cell lung

1		
2		
3		
4		
5		
6		
/		
8		
9 10		
10		
12		
13		
14		
15		
16		
17		
18		
19		
20		
21		
22		
25 24		
24		
26		
27		
28		
29		
30		
31		
32		
33		
34		
35		
36		
3/ 20		
30		
40		
41		
42		
43		
44		
45		
46		
47		
48		
49		
50 51		
51 52		
52 52		
54		
55		
56		
57		
58		
59		
60		

4	Xiongfeng Huang ¹ , Donghong Zhu ² , Yaoxing Cao ³ , Weijuan Li ¹ , Jinxing Lai ⁴ , Yuxi
5	Ren ⁵ *
6	1. Fuzhou Medical College, Nanchang University, Fuzhou, China.
7	2. Department of Respiratory, The Ninth Hospital of Nanchang, Nanchang, China.
8	3. Jiangxi College of Traditional Chinese Medicine, Fuzhou, China.
9	4. Affiliated Ganzhou Hospital of Nanchang University, Ganzhou, China.
10	5. Jiangxi University of Traditional Chinese Medicine, Nanchang, China.
11	*Correspondence: Yuxi Ren. E-mail: renyuxi009@163.com
12	
13	ABSTRACT
14	Introduction
15	Lung cancer remains the primary cause of cancer-related deaths on a global scale.
16	Surgery is the main therapeutic option for non-small cell lung cancer (NSCLC).
17	However, the optimal surgical approach for lymph node assessment in NSCLC
18	resection remains controversial, and it's still uncertain whether lymph node dissection
19	(LND) is more effective in reducing recurrence and metastasis rates in NSCLC
20	compared to lymph node sampling (LNS). Therefore, we will conduct a meta-analysis
21	to evaluate the recurrence and metastasis of LND versus LNS in patients with NSCLC.
22	Methods and analysis
23	This systematic review and meta-analysis will follow the Preferred Reporting Items for
24	Systematic Reviews and Meta-Analysis: The PRISMA Statement. According to the
25	predefined inclusion criteria, we will conduct a comprehensive search for randomized
26	controlled trials (RCTs) and non-randomized studies examining the recurrence and
27	metastasis of LND compared to LNS in patients with NSCLC. A literature search from
28	inception in PubMed, EMBASE, the Cochrane Library, CNKI, WanFang, Sinomed,
29	VIP, and Web of Science. There will be no limitations on language, and the search will $^{\ 1}$
	For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Yuxi

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

BMJ Open

כ ₄
4
5
6
7
8
9
10
11
17
12
13
14
15
16
17
18
19
20
∠∪ ว1
21
22
23
24
25
26
27
28
20
29
30
31
32
33
34
35
36
37
20
38
39
40
41
42
43
44
45
46
40 47
+/ 40
40 40
49
50
51
52
53
54
55
55
50
5/
58
59
60

1 2

be undertaken on 30 August 2024 with regular search for new studies. Additionally, 30 relevant literature references will be retrieved and hand searching of pertinent journals 31 32 will be conducted. The main outcomes include overall recurrence rate, local recurrence rate, and distant metastasis rate. The supplementary outcomes encompass the rates of 33 regional recurrence and lymph node metastasis. Two independent reviewers will 34 perform screening, data extraction, and quality assessment. Our reviewers will perform 35 subgroup analysis, sensitivity analysis, and publication bias analysis to evaluate the 36 heterogeneity and robustness. Review Manager 5.4 will be applied in analyzing and 37 synthesizing. The Grading of Recommendations Assessment, Development and 38 Evaluation (GRADE) will be used to assess the quality of evidence for the whole study. 39 **Ethics and dissemination** 40

Ethical approval is dispensable for this study since no private information of the
participants will be involved. The findings of the present study will be disseminated
through a peer-reviewed journal or conference presentation.

44 Study registration

45 The protocol of the systematic review has been registered on Open Science Framework,

46 with a registration DOI https://doi.org/10.17605/OSF.IO/S2FT5.

47 STRENGTHS AND LIMITATIONS OF THIS STUDY

- 48 > This protocol follows the Preferred Reporting Items for Systematic Review and
 49 Meta-Analysis Protocols (PRISMA-P) guidelines.
- To minimize the risk of bias, two researchers will independently carry out the study
 selection, data extraction, and quality assessment.
- Non-randomized studies may introduce methodological limitations and affect the
 overall quality of evidence.
- The potential existence of significant heterogeneity among various studies could
 hinder the derivation of causal conclusions from their combined findings.
- Because our search will focus primarily on English and Chinese databases, there is
 a possibility of overlooking studies in other languages, which could result in
 language bias.

INTRODUCTION

Non-small cell lung cancer (NSCLC), the predominant form of lung malignancy, continues to pose a significant threat to global health. In 2024, the American Cancer Society estimated that lung cancer is the leading cause of cancer death, with an estimated 340 people dying from lung cancer every day, almost 2.5 times more than colorectal cancer, which ranks second in cancer deaths.[1] Lung cancer remains the primary cause of cancer-related deaths on a global scale.[2-5]

Surgical resection plays a crucial role in the management of NSCLC, and lymph node staging is essential for accurate prognostication and treatment planning. Lymph node dissection (LND) and lymph node sampling (LNS) are two surgical techniques used for NSCLC, but their relative effectiveness remains controversial.[6-15] LNS involves the removal of a smaller number of lymph nodes for pathological examination. This approach is generally less invasive, leading to shorter operative times and potentially fewer postoperative complications.[16] However, it may not provide as comprehensive nodal staging as dissection, leading to potential underestimation of the disease stage. LND, conversely, involves the complete removal of lymph nodes and surrounding tissue in specific anatomic regions. This approach offers a comprehensive assessment of nodal involvement, allowing for more accurate staging and potentially improving long-term outcomes. However, it is a more invasive procedure that may increase the risk of post-operative complications, which may result in a reduction in postoperative quality of life for patients. Furthermore, for some patients with early NSCLC, the incidence of lymph node metastasis is not very high, and most patients may not have regional lymph node metastasis. Thus, the necessity of performing complete and systematic lymph node dissection in patients with NSCLC and whether the expected clinical effect can be achieved remains controversial.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies

Patients with NSCLC continue to experience a notable rate of recurrence and metastasis following surgical intervention, thereby impacting their overall survival outcomes. A meta-analysis of 11 observational studies showed that surgery decreased the risk of NSCLC recurrence in stage I–IV. [17] And several studies have compared

the recurrence and metastasis of LND and LNS in NSCLC surgery. Based on three previous studies, [18-20] LND has been shown to reduce the incidence of recurrence and metastasis in NSCLC. And Meng et al. [21] have posited in their meta-analysis that the use of LND may be effective in eliminating hidden micrometastases to reduce the risk of both local recurrence and distant metastases. However, the results of our previous meta-analysis indicated that in individuals with NSCLC, LND and LNS yielded similar rates of recurrence and metastasis.[22] Additionally, other studies have also shown that lymph node dissection conducted in lung cancer does not impact the occurrence of recurrence and metastasis.[23-25]

The optimal surgical approach for lymph node assessment in NSCLC resection remains controversial, and it's still uncertain whether LND is more effective in reducing recurrence and metastasis rates in NSCLC compared to LNS. Clearly, newer systematic review and meta-analyses are required to resolve this issue, and definitive analyses can provide stronger rationales for the choice of a specific therapy. Consequently, we will perform a meta-analysis of relevant randomized controlled trials (RCTs) and non-randomized studies to evaluate the recurrence and metastasis of LND versus LNS in NSCLC patients. We hope this meta-analysis will offer strong evidence for the surgical treatment of patients with NSCLC and guide future clinical practice.

107 MATERIALS AND METHODS

Registration and reporting

109 This review protocol has been officially registered in the Open Science Framework 110 (OSF) database (DOI https://doi.org/10.17605/OSF.IO/S2FT5). And the results will be 111 reported in accordance with the Preferred Reporting Items for Systematic Reviews and 112 Meta-Analyses Protocols (PRISMA-P) statement (supplemental File 1).[26] If there is 113 a change to this protocol, details of the amendment and the reasons for it will be added 114 to OSF. The systematic review and meta-analysis is anticipated to commence on August 115 30th and conclude on December 30th.

59 117 Eligibility criteria

Types of studies

All relevant published RCTs and non-randomized studies will be included. The review
will not include certain types of studies, such as methodological papers, editorials,
qualitative research, individual case reports, and secondary studies like narrative
reviews, systematic reviews and meta-analyses. There will be no restrictions on the
language used or the time of publication.

Types of participants

125 Individuals with NSCLC who received either LND or LNS will be eligible for inclusion,

126 with no limitations based on country, race, ethnicity, age, gender, or occupation.

Type of outcomes

The main outcomes are as follows: overall recurrence rate, local recurrence rate (ipsilateral lung, ipsilateral pleura, trachea, etc.), and distant metastasis rate (contralateral lung, contralateral pleura, bone, liver, etc.). The supplementary outcomes encompass the rates of regional recurrence and lymph node metastasis. Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

132 Inf

2 Information source and search strategy

A literature search from inception in PubMed, EMBASE, the Cochrane Library, CNKI, WanFang, Sinomed, VIP, and Web of Science. The Gray Journal includes annual meetings of the American Society of Clinical Oncology and the American Society of Thoracic Surgery (chest surgery), using combinations of the search terms: lymph node dissection, LND, lymph node sampling, LNS, and non-small cell lung cancer, NSCLC. Detailed search strategies are shown in supplemental File 2. There will be no limitations on language, and the search will be undertaken on 30 August 2024 with regular search for new studies. The bibliography of all articles obtained will be examined to identify additional publications that may be pertinent. In addition, abstracts from the American Society of Clinical Oncology and the European Society of Medical Oncology will be searched for potential studies. In order to gather thorough information from qualifying studies, we will contact primary authors to request any pertinent data, such as supplementary materials that may not have been fully disclosed or reported, and information from informal sources related to the research. Two reviewers will examine the reference list and individually choose the studies.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Study Selection

The chosen articles will undergo a dual review process by two separate authors. Following the initial screening of titles and abstracts of papers found through the search strategy, the papers will be sorted into two categories: potentially relevant or not relevant based on the eligibility criteria. Subsequently, efforts will be made to obtain the full texts of all potentially relevant papers, which will then be reviewed against the eligibility criteria. In the event of disagreements during the full-text screening, they will be resolved through discussion. If a consensus cannot be reached, a third author will step in to settle the dispute. The study selection process is illustrated in Figure 1.

Data extraction process

The data will be taken from each full-text article that meets the eligibility criteria: study design; country of study; interventions; outcomes; number and general characteristics of participants, for example, age, and gender. The process of data extraction will be conducted by two reviewers, with Microsoft Excel being employed as the tool for data collection. Any disagreements between the two reviewers will be resolved by discussion or by consulting with the third reviewer, the characteristics of the study are attached as Supplemental File 3.

Dealing with missing data

In cases where data is unavailable, two reviewers will make efforts to contact the original authors via email or phone to request supplementary information. Should the data remain unattainable, the study will be omitted from the analysis. The potential influence of missing data on the comprehensive analysis will be evaluated through sensitivity analysis.

Study risk of bias assessment

Two reviewers will assess the quality of the included studies. Disagreement between the two reviewers will be resolved by discussion with the third reviewer.

We will evaluate the included RCTs' quality using the Cochrane Handbook's "risk of bias" technique.[27] Sequence generation, allocation concealment, blinding, incomplete data, and selective reporting were assessed, and each of them was graded as "yes(+)", "no(-)" or "unclear(?)", which reflected low risk of bias, high risk of bias,

and uncertain risk of bias, respectively.[28] The Newcastle-Ottawa scale will be used to evaluate the methodological rigor of non-randomized studies. The Newcastle-Ottawa Scale consists of eight items that are divided into three categories: selection (four items, one star each), comparability (one item, up to two stars), and exposure/outcome (three items, one star each).[29] One star will be given for each item in the selection and outcome domains, and up to two stars will be given for the comparability domain, when a primary study satisfies the methodological required standard. Studies with star values between 0 and 4 will ultimately be classified as having a high risk of bias, studies with scores between 5 and 6 as having a moderate risk of bias, and studies with scores between 7 and 9 as having a low risk of bias.[30]

Patient and public involvement

Since this study will focus on reviewing existing literature, there will be no direct participation of patients or the public. While patients will not be engaged in data collection or analysis for this review, their input, along with that of the public, will be considered in shaping future research stemming from this study.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

DATA ANALYSIS

Statistical analysis

Meta-analysis will be planned with sufficient clinically and statistically homogeneous and comparable reported outcomes among studies by pooling data using Review Manager V.5.4 software by The Cochrane Collaboration. Dichotomous data will be compared using a risk ratio (RR) or odds ratio (OR). Respective 95% confidence intervals (CI) will be calculated for each estimate and presented in forest plots.

Statistical heterogeneity will be assessed visually by Q and I^2 statistics.[31] For the Q statistic, a *P* value<0.10 Will be regarded as statistically significant for heterogeneity. For the I^2 statistic, [32] if there is heterogeneity among the study results ($I^2 > 50\%$), the heterogeneity source will be further examined. After the exclusion of effects exerted by significant clinical heterogeneity, the random-effects model will be employed for the meta-analysis. [33, 34] If there is no heterogeneity between the study results ($I^2 < 50\%$), this study will use the fixed-effect model in terms of meta-analysis.[35, 36] All reported

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

P-values are 2-sided and values of P < 0.05 will be regarded as significant for all included studies. In cases of significant heterogeneity encountered during the meta-analysis procedure, several strategies will be implemented. Firstly, a subgroup analysis will be conducted to classify studies according to potential sources of heterogeneity, leading to separate meta-analyses for each subgroup. Secondly, meta-regression techniques will be employed to examine study attributes and pinpoint factors that may be influencing the observed heterogeneity. Lastly, if challenges with high heterogeneity persist, the option of transforming the meta-analysis into a systematic review will be considered, allowing for a qualitative synthesis of studies without quantitative amalgamation.

217 Assessment of publication bias

The funnel plot will be used to assess reporting bias. A symmetrical funnel shape will suggest the absence of publication bias, whereas an asymmetrical funnel plot will indicate the presence of such bias. An objective assessment of publication bias will be conducted employing Egger's linear regression test, where a p-value less than 0.1 is considered statistically significant, indicating the presence of publication bias.[37, 38] And we will conduct a trim and fill analysis to address any potential publication bias. This method involves excluding outlier studies and estimating hypothetical missing studies to create a balanced funnel plot.

226 Subg

5 Subgroup and sensitivity analyses

Subgroup analyses will be conducted based on study and population variables, including study type, age, gender, intervention approaches, sample size, and other factors. For sensitivity analysis, studies of poorer methodological quality will be removed to see if their deletion alters the outcomes of the analyses. In particular, we will exclude non-randomized studies deemed to be of low quality (rated between 0 and 4 stars) and those RCTs identified as having a high risk of bias. This methodology will enable us to evaluate the reliability of our findings and pinpoint any potential sources of bias. When heterogeneity is substantial, the leave-one-out method is employed to ascertain whether it arises from a specific study. For instance, to ascertain whether

Page 9 of 25

BMJ Open

heterogeneity diminishes, we eliminate one study. This approach is employed to investigate each study individually, in order to identify the root cause of heterogeneity.

238 Grading the quality of evidence

The evaluation of the evidence's quality throughout the entire study will be conducted utilizing the GRADE (Grading of Recommendations Assessment, Development and Evaluation) framework.[39-41] This system is frequently employed to evaluate the credibility of evidence and determine the level of recommendations. Two independent reviewers will employ the five GRADE considerations, including the risk of bias, consistency of effect, imprecision, indirectness, and publication bias, to meticulously evaluate the certainty of the evidence and arrive at sound conclusions.[42, 43] Verification will be carried out upon completion, and any uncertainties will be deliberated among reviewers or escalated to a third expert for guidance.

The level of evidence will be assessed and categorized as high, moderate, low, or very low. RCT evidence is initially considered to have a high level of certainty, but this evaluation may be adjusted downwards if factors such as risk of bias, indirectness, inconsistency, imprecision, and publication bias are identified. On the other hand, evidence from observational studies is typically assigned a low level of certainty, but this rating may be elevated if there is evidence for a large magnitude of effect, mitigation of potential bias or confounding factors, leading to an upgrade from the initial low rating. Strong recommendations are made when there is a high level of evidence, while practice considerations are given when there is a moderate level of evidence. When the evidence level is below moderate, it is stated that there is insufficient evidence from scientific literature to provide guidance to policymakers, clinicians, and patients.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

260 Updates to study protocol

If modifications to the review protocol are deemed necessary, these adjustments will be
thoroughly documented and incorporated as supplementary material alongside the final
manuscript. Additionally, these updates will be reflected on the OSF register for future
reference.

265 Ethics and dissemination

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

BMJ Open

Ethical approval is dispensable for this study since no private information of the
participants will be involved. The findings of the present study will be disseminated
through a peer-reviewed journal or conference presentation.

269 Author contributions

XH conceived the study. XH and YC registered the protocol. XH and WL drafted the
protocol. YC and JL revised it. XH and YR developed the search strategies and will run
them. XH and YR will select studies and extract data. XH and DZ will analyze the data.
All authors contributed to the article and approved the submitted version. XH is the
guarantor.

275 Funding

Science and technology project of Fuzhou Medical College of Nanchang University
(fykj202404); Science and technology project of Jiangxi Provincial Administration of
Traditional Chinese Medicine (2023A0289); Science and technology project of Jiangxi
Provincial Administration of Traditional Chinese Medicine (2022B1103); Jiangxi
Province key research and development program (2020YBBGWL001), Jiangxi
Provincial Department of Education Science and Technology research key project
(GJJ208902).

- **Competing interests**
- 284 The authors declare no conflict of interest.
 - 285 Word count
 - 286 2314 words

REFERENCES

- 289 1. Siegel RL, Giaquinto AN. Cancer statistics, 2024. *CA: a cancer journal for clinicians*290 2024;74(1):12-49. doi: 10.3322/caac.21820
- 291 2. Bade BC, Dela Cruz CS. Lung Cancer 2020: Epidemiology, Etiology, and Prevention. *Clinics in* 292 *chest medicine* 2020;41(1):1-24. doi: 10.1016/j.ccm.2019.10.001 [published Online First:
 293 2020/02/06]
- 294 3. Herbst RS, Heymach JV, Lippman SM. Lung cancer. The New England journal of medicine

BMJ Open

2 3		
$\begin{array}{c} 4\\ 5\\ 6\\ 7\\ 8\\ 9\\ 10\\ 11\\ 12\\ 13\\ 14\\ 15\\ 16\\ 17\\ 18\\ 19\\ 20\\ 21\\ 22\\ 32\\ 4\\ 25\\ 26\\ 27\\ 28\\ 29\\ 30\\ 31\\ 32\\ 33\\ 45\\ 36\\ 37\\ 38\\ 9\\ 40\\ 41\\ 42\\ 43\\ 44\\ 546\\ 47\\ 48\\ 49\\ 50\\ 51\\ 52\\ 53\\ 54\\ 55\\ 56\\ 57\\ 58\\ 9\\ 60\\ \end{array}$	295	2008;359(13):1367-80. doi: 10.1056/NEJMra0802714 [published Online First: 2008/09/26]
	296	4. Gridelli C, Rossi A, Maione P, et al. Vaccines for the treatment of non-small cell lung cancer: a
	297	renewed anticancer strategy. The oncologist 2009;14(9):909-20. doi:
	298	10.1634/theoncologist.2009-0017 [published Online First: 2009/09/04]
	299	5. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA: a cancer journal for clinicians
	300	2011;61(2):69-90. doi: 10.3322/caac.20107 [published Online First: 2011/02/08]
	301	6. Xu J, Lai J, Huang X. Survival outcomes following complete mediastinal lymphadenectomy or
	302	selective mediastinal lymphadenectomy in patients with stage I-IIIA non-small cell lung cancer:
	303	protocol for a systematic review and meta-analysis. BMJ Open 2024;14(3):e084520. doi:
	304	10.1136/bmjopen-2024-084520
	305	7. Zhang Y, Deng C, Zheng Q, et al. Selective Mediastinal Lymph Node Dissection Strategy for
	306	Clinical T1N0 Invasive Lung Cancer: A Prospective, Multicenter, Clinical Trial. Journal of
	307	thoracic oncology : official publication of the International Association for the Study of Lung
	308	Cancer 2023;18(7):931-39. doi: 10.1016/j.jtho.2023.02.010 [published Online First:
	309	2023/02/26]
	310	8. Wang Y, Darling GE. Complete mediastinal lymph node dissection versus systematic lymph node
	311	sampling in surgical treatment of non-small cell lung cancer: do we have the answer? Journal
	312	of thoracic disease 2017;9(11):4169-70. doi: 10.21037/jtd.2017.10.39 [published Online First:
	313	2017/12/23]
	314	9. Xu F, Qi L, Yue D, et al. The effect of the extent of lymph node dissection for stage IA non-
	315	small-cell lung cancer on patient disease-free survival. Clinical lung cancer 2013;14(2):181-7.
	316	doi: 10.1016/j.cllc.2012.09.002 [published Online First: 2012/12/01]
	317	10. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the
	318	published literature for survival endpoints. Statistics in medicine 1998;17(24):2815-34. doi:
	319	10.1002/(sici)1097-0258(19981230)17:24<2815::aid-sim110>3.0.co;2-8 [published Online
	320	First: 1999/01/28]
	321	11. Ou SH, Zell JA. Prognostic significance of the number of lymph nodes removed at lobectomy
	322	in stage IA non-small cell lung cancer. Journal of thoracic oncology : official publication of the
	323	International Association for the Study of Lung Cancer 2008;3(8):880-6. doi:
	324	10.1097/JTO.0b013e31817dfced [published Online First: 2008/08/02] 11
Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

325 12. Wang Z, Qi Z, Cheng D, et al. Lobe-Specific Node Dissection Can Be a Suitable Alternative to
326 Systematic Lymph Node Dissection in Highly Selective Early-Stage Non-Small-Cell Lung
327 Cancer Patients: A Meta-Analysis. *Annals of thoracic and cardiovascular surgery : official*328 *journal of the Association of Thoracic and Cardiovascular Surgeons of Asia* 2021;27(3):143-

13. Tantraworasin A, Saeteng S, Siwachat S, et al. Impact of lymph node management on resectable
non-small cell lung cancer patients. *Journal of thoracic disease* 2017;9(3):666-74. doi:
10.21037/jtd.2017.02.90 [published Online First: 2017/04/30]

50. doi: 10.5761/atcs.oa.20-00136 [published Online First: 2020/12/08]

- 14. Yang M, Cao H, Guo X, et al. The number of resected lymph nodes (nLNs) combined with
 tumor size as a prognostic factor in patients with pathologic N0 and Nx non-small cell lung
 cancer. *PloS one* 2013;8(9):e73220. doi: 10.1371/journal.pone.0073220 [published Online First:
 2013/09/12]
- 337 15. Wang W, Chen D, Xi K, et al. Impact of Different Types of Lymphadenectomy Combined With
 338 Different Extents of Tumor Resection on Survival Outcomes of Stage I Non-small-cell Lung
 339 Cancer: A Large-Cohort Real-World Study. *Frontiers in oncology* 2019;9:642. doi:
 340 10.3389/fonc.2019.00642 [published Online First: 2019/08/10]
- 341 16. Dezube AR, Mazzola E, Bravo-Iñiguez CE, et al. Analysis of Lymph Node Sampling Minimums
 342 in Early Stage Non-Small-Cell Lung Cancer. *Seminars in thoracic and cardiovascular surgery* 343 2021;33(3):834-45. doi: 10.1053/j.semtcvs.2020.11.007 [published Online First: 2020/11/13]
- 344 17. Hu J, Miao H, Li R, et al. Surgery and subsequent risk of non-small cell lung cancer recurrence:
 345 a meta-analysis of observational studies. *Translational cancer research* 2020;9(3):1960-68. doi:
 346 10.21037/tcr.2020.02.15
 - 347 18. Wu Y, Huang ZF, Wang SY, et al. A randomized trial of systematic nodal dissection in
 348 resectable non-small cell lung cancer. *Lung cancer (Amsterdam, Netherlands)* 2002;36(1):1-6.
 349 doi: 10.1016/s0169-5002(01)00445-7 [published Online First: 2002/03/14]
 - 350 19. Su X, Wang X, Long H, et al. Mediastinal lymph node dissection affects survival in patients
 351 with stage I non-small cell lung cancer. *The Thoracic and cardiovascular surgeon*352 2008;56(4):226-30. doi: 10.1055/s-2007-989494 [published Online First: 2008/05/16]
- 353 20. Lardinois D, Suter H, Hakki H, et al. Morbidity, survival, and site of recurrence after mediastinal
 - 354 lymph-node dissection versus systematic sampling after complete resection for non-small cell12

BMJ Open

355	lung cancer. The Annals of thoracic surgery 2005;80(1):268-74; discussion 74-5. doi:
356	10.1016/j.athoracsur.2005.02.005 [published Online First: 2005/06/25]
357	21. Meng D, Zhou Z, Wang Y, et al. Lymphadenectomy for clinical early-stage non-small-cell lung
358	cancer: a systematic review and meta-analysis. European journal of cardio-thoracic surgery :
359	official journal of the European Association for Cardio-thoracic Surgery 2016;50(4):597-604.
360	doi: 10.1093/ejcts/ezw083 [published Online First: 2016/04/24]
361	22. Huang X, Wang J, Chen Q, et al. Mediastinal lymph node dissection versus mediastinal lymph
362	node sampling for early stage non-small cell lung cancer: a systematic review and meta-analysis.
363	PloS one 2014;9(10):e109979. doi: 10.1371/journal.pone.0109979 [published Online First:
364	2014/10/09]
365	23. Mokhles S, Macbeth F, Treasure T, et al. Systematic lymphadenectomy versus sampling of
366	ipsilateral mediastinal lymph-nodes during lobectomy for non-small-cell lung cancer: a
367	systematic review of randomized trials and a meta-analysis. European journal of cardio-
368	thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
369	2017;51(6):1149-56. doi: 10.1093/ejcts/ezw439 [published Online First: 2017/02/06]
370	24. Luo J, Yang S, Dong S. Selective Mediastinal Lymphadenectomy or Complete Mediastinal
371	Lymphadenectomy for Clinical Stage I Non-Small Cell Lung Cancer: A Meta-Analysis.
372	2021;38(12):5671-83. doi: 10.1007/s12325-021-01954-w
373	25. Darling GE, Allen MS, Decker PA, et al. Randomized trial of mediastinal lymph node sampling
374	versus complete lymphadenectomy during pulmonary resection in the patient with N0 or N1
375	(less than hilar) non-small cell carcinoma: results of the American College of Surgery Oncology
376	Group Z0030 Trial. The Journal of thoracic and cardiovascular surgery 2011;141(3):662-70.
377	doi: 10.1016/j.jtcvs.2010.11.008 [published Online First: 2011/02/22]
378	26. Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and
379	meta-analysis protocols (PRISMA-P) 2015 statement. Systematic reviews 2015;4(1):1. doi:
380	10.1186/2046-4053-4-1 [published Online First: 2015/01/03]
381	27. Higgins JP, Thomas J, Chandler J, et al. Cochrane Handbook for Systematic Reviews of
382	Interventions version 6.4 (updated August 2023). Cochrane 2023
383	28. Higgins JP, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration's tool for assessing
384	risk of bias in randomised trials. <i>BMJ (Clinical research ed)</i> 2011;343:d5928. doi: 13

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

BMJ Open



BMJ Open

2		
3 4	415	Gesundheitswesen 2013;107(9-10):646-64. doi: 10.1016/j.zefq.2013.10.034 [published Online
5 6	416	First: 2013/12/10]
7 8	417	40. Guyatt GH, Oxman AD, Kunz R, et al. What is "quality of evidence" and why is it important to
9 10	418	clinicians? BMJ (Clinical research ed) 2008;336(7651):995-8. doi:
11 12	419	10.1136/bmj.39490.551019.BE [published Online First: 2008/05/06]
13 14	420	41. Guyatt GH, Oxman AD, Kunz R, et al. GRADE guidelines: 2. Framing the question and deciding
15 16	421	on important outcomes. Journal of clinical epidemiology 2011;64(4):395-400. doi:
17 18	422	10.1016/j.jclinepi.2010.09.012 [published Online First: 2011/01/05]
19 20	423	42. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of
21 22	424	evidence and strength of recommendations. BMJ (Clinical research ed) 2008;336(7650):924-6.
23 24	425	doi: 10.1136/bmj.39489.470347.AD [published Online First: 2008/04/26]
25	426	43. H S, Brozek J, Oxman AE. GRADE handbook for grading quality of evidence and strength of
27	427	recommendation. 2009
20 29 20	428	
30 31 32	429	Appendices
33 34	430	Fig 1. Flow diagram showing the selection process of articles.
35 36	431	Supplemental File 1. PRISMA-P-checklist.
37 38	432	Supplemental File 2. Search strategy.
39 40	433	Supplemental File 3. General information of the included studies.
41 42		
43		
45		
46 47		
48		
49		
50 51		
52		
53		
54		
55 56		
57		
58		
59 60		

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

PRISMA 2020 flow diagram for new systematic reviews which included searches of databases and registers only



*Consider, if feasible to do so, reporting the number of records identified from each database or register searched (rather than the total number across all databases/registers).

**If automation tools were used, indicate how many records were excluded by a human and how many were excluded by automation tools.

From: Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71. doi: 10.1136/bmj.n71

For more information, visit: http://www.prisma-statement.org/

		copyrig
PRISMA-P (P address in a sy	referre stemati	d Reporting Items for Systematic review and Meta-Analysis Protocols) 2015 checklist: recommended ic review protocol*
Section and topic	Item No	Checklist item of 22
ADMINISTRAT	VE INF	
Title:		eligne at the second
Identification	1a	Identify the report as a protocol of a systematic review
Update	1b	If the protocol is for an update of a previous systematic review, identify as such
Registration	2	If registered, provide the name of the registry (such as PROSPERO) and registration number
Authors:		and
Contact	3a	Provide name, institutional affiliation, e-mail address of all protocol authors; provide physical main address of correspondiauthor
Contributions	3b	Describe contributions of protocol authors and identify the guarantor of the review
Amendments	4	If the protocol represents an amendment of a previously completed or published protocol, identified as such and list changes; otherwise, state plan for documenting important protocol amendments
Support:		
Sources	5a	Indicate sources of financial or other support for the review
Sponsor	5b	Provide name for the review funder and/or sponsor
Role of spons or funder	or 5c	Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol
INTRODUCTIO	N	
Rationale	6	Describe the rationale for the review in the context of what is already known
Objectives	7	Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO)
METHODS		gies
Eligibility criteria	8	Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as years considered, language, publication status) to be used as criteria for eligibility for the review
Information source	es 9	Describe all intended information sources (such as electronic databases, contact with study authors, trail registers or other gree literature sources) with planned dates of coverage
Search strategy	10	Present draft of search strategy to be used for at least one electronic database, including planned limit such that it could be repeated
		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

3

		BMJ Open by jo. co ee	
		pyrig	
		ht, i	
tudy records:			
Data management	11a	Describe the mechanism(s) that will be used to manage records and data throughout the review $\begin{bmatrix} a & b \\ b & c \\ c & c$	P6
Selection process	11b	State the process that will be used for selecting studies (such as two independent reviewers) through each phase of the review (that is, screening, eligibility and inclusion in meta-analysis)	P6
Data collection process	11c	Describe planned method of extracting data from reports (such as piloting forms, done independent of the processes for obtaining and confirming data from investigators	P6
Data items	12	List and define all variables for which data will be sought (such as PICO items, funding sources) to be a sumptions and simplifications	P6
Outcomes and rioritization	13	List and define all outcomes for which data will be sought, including prioritization of main and a definitional and a definition of main and a def	P5
tisk of bias in ndividual studies	14	Describe anticipated methods for assessing risk of bias of individual studies, including whether the outcome or study level, or both; state how this information will be used in data synthesis	P6-7
Data synthesis	15a	Describe criteria under which study data will be quantitatively synthesised	P7-8
	15b	If data are appropriate for quantitative synthesis, describe planned summary measures, methods of combining data from studies, including any planned exploration of consistency (such as I ² , Kendal's s)	P7-8
	15c	Describe any proposed additional analyses (such as sensitivity or subgroup analyses, meta-regreszionz	P8-9
	15d	If quantitative synthesis is not appropriate, describe the type of summary planned	P8
leta-bias(es)	16	Specify any planned assessment of meta-bias(es) (such as publication bias across studies, selectized regording within studies)	P8
Confidence in umulative evidence	17	Describe how the strength of the body of evidence will be assessed (such as GRADE)	P9
It is strongly recon larification on the i PRISMA-P Group a From: Shamseer L, M neta-analysis protoco	nmend tems. A and is d loher 1 pols (PR	ed that this checklist be read in conjunction with the PRISMA-P Explanation and Elaboratien (Gte when available) for im Amendments to a review protocol should be tracked and dated. The copyright for PRISMA-P. Iistributed under a Creative Commons Attribution Licence 4.0. D, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart L, PRISMA-P Group. Preferring items for systemati RISMA-P) 2015: elaboration and explanation. BMJ. 2015 Jan 2;349(jan02 1):g7647.	portant by the c review and
		vgies.	
		igence	
		Bibliographiqu	
		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

Supplementary file 2. Search strategy

1. PubMed

Number	Search terms
#1	Non-Small-Cell OR Non-Small-Cell Lung Carcinomas OR Non-Small
	Cell Lung Cancer OR Non-Small-Cell Lung Carcinoma OR Non-Small
	Cell Lung Carcinoma OR Non-Small Cell Lung OR Non-Small Cell Lung
	Cancer OR Lung Neoplasms OR Pulmonary Neoplasms OR Lung
	Neoplasm OR Pulmonary Neoplasm OR Lung Cancer OR Lung Cancers
	OR Pulmonary Cancer OR Pulmonary Cancers OR Cancer of the Lung
	OR Cancer of Lung OR Non-Small-Cell Lung OR Lung Carcinoma OR
	Non-Small-Cell OR Lung Carcinomas OR NSCLC [Title/Abstract]
#2	Surgical Procedures OR Operative OR surgery OR surgery OR surgical
	OR operative OR postoperative [Title/Abstract]
#3	lymphadenectomy OR lymphadenectomy OR complete mediastinal
	lymphadenectomy OR mediastinal lymph node excision OR lobe-specific
	lymph node dissection OR mediastinal lymph node dissection OR
	mediastinal lymph node sampling OR lymph node dissection OR lymph
	node OR dissect OR sample OR selective mediastinal lymphadenectomy
	OR systematic lymph node dissection OR selective lymph node dissection
	OR LND OR LNS [Title/Abstract]
#4	randomly OR randomized OR RCT OR trials OR cohort OR longitudinal
	OR prospective OR survival [Title/Abstract]
#5	#1 AND #2 AND #3 AND #4 [Title/Abstract]
2. Embas	e O

2. Embase

Number	Search terms
#1	Non-Small-Cell:ti,ab,kw OR Non-Small-Cell Lung Carcinomas:ti,ab,kw
	OR Non-Small Cell Lung Cancer:ti,ab,kw OR Non-Small-Cell Lung
	Carcinoma:ti,ab,kw OR Non-Small Cell Lung Carcinoma:ti,ab,kw OR
	Non-Small Cell Lung:ti,ab,kw OR Non-Small Cell Lung Cancer:ti,ab,kw
	OR Lung Neoplasms:ti,ab,kw OR Pulmonary Neoplasms:ti,ab,kw OR
	Lung Neoplasm:ti,ab,kw OR Pulmonary Neoplasm:ti,ab,kw OR Lung
	Cancer:ti,ab,kw OR Lung Cancers:ti,ab,kw OR Pulmonary
	Cancer:ti,ab,kw OR Pulmonary Cancers:ti,ab,kw OR Cancer of the
	Lung:ti,ab,kw OR Cancer of Lung:ti,ab,kw OR Non-Small-Cell
	Lung:ti,ab,kw OR Lung Carcinoma:ti,ab,kw OR Non-Small-Cell:ti,ab,kw
	OR Lung Carcinomas:ti,ab,kw OR NSCLC:ti,ab,kw
#2	Surgical Procedures:ti,ab,kw OR Operative OR surgery:ti,ab,kw OR
	surgery:ti,ab,kw OR surgical:ti,ab,kw OR operative:ti,ab,kw OR
	postoperative:ti,ab,kw

#3	lymphadenectomy:ti,ab,kw OR lymphadenectomy:ti,ab,kw OR complete
	mediastinal lymphadenectomy:ti,ab,kw OR mediastinal lymph node
	excision:ti,ab,kw OR lobe-specific lymph node dissection:ti,ab,kw OR
	mediastinal lymph node dissection:ti,ab,kw OR mediastinal lymph node
	sampling:ti,ab,kw OR lymph node dissection:ti,ab,kw OR lymph
	node:ti,ab,kw OR dissect:ti,ab,kw OR sample:ti,ab,kw OR selective
	mediastinal lymphadenectomy:ti,ab,kw OR systematic lymph node
	dissection:ti,ab,kw OR selective lymph node dissection:ti,ab,kw OR
	LND:ti,ab,kw OR LNS:ti,ab,kw
#4	randomly:ti,ab,kw OR randomized:ti,ab,kw OR RCT:ti,ab,kw OR
	trials:ti,ab,kw OR cohort:ti,ab,kw OR longitudinal:ti,ab,kw OR
	prospective:ti,ab,kw OR survival:ti,ab,kw
#5	#1 AND #2 AND #3 AND #4

3. Cochrane Library

Number	Search terms
#1	Non-Small-Cell:ti,ab,kw OR Non-Small-Cell Lung Carcinomas:ti,ab,kw
	OR Non-Small Cell Lung Cancer:ti,ab,kw OR Non-Small-Cell Lung
	Carcinoma:ti,ab,kw OR Non-Small Cell Lung Carcinoma:ti,ab,kw OR
	Non-Small Cell Lung:ti,ab,kw OR Non-Small Cell Lung Cancer:ti,ab,kw
	OR Lung Neoplasms:ti,ab,kw OR Pulmonary Neoplasms:ti,ab,kw OR
	Lung Neoplasm:ti,ab,kw OR Pulmonary Neoplasm:ti,ab,kw OR Lung
	Cancer:ti,ab,kw OR Lung Cancers:ti,ab,kw OR Pulmonary
	Cancer:ti,ab,kw OR Pulmonary Cancers:ti,ab,kw OR Cancer of the
	Lung:ti,ab,kw OR Cancer of Lung:ti,ab,kw OR Non-Small-Cell
	Lung:ti,ab,kw OR Lung Carcinoma:ti,ab,kw OR Non-Small-Cell:ti,ab,kw
	OR Lung Carcinomas:ti,ab,kw OR NSCLC:ti,ab,kw
#2	Surgical Procedures:ti,ab,kw OR Operative OR surgery:ti,ab,kw OR
	surgery:ti,ab,kw OR surgical:ti,ab,kw OR operative:ti,ab,kw OR
	postoperative:ti,ab,kw
#3	lymphadenectomy:ti,ab,kw OR lymphadenectomy:ti,ab,kw OR complete
	mediastinal lymphadenectomy:ti,ab,kw OR mediastinal lymph node
	excision:ti,ab,kw OR lobe-specific lymph node dissection:ti,ab,kw OR
	mediastinal lymph node dissection:ti,ab,kw OR mediastinal lymph node
	sampling:ti,ab,kw OR lymph node dissection:ti,ab,kw OR lymph
	node:ti,ab,kw OR dissect:ti,ab,kw OR sample:ti,ab,kw OR selective
	mediastinal lymphadenectomy:ti,ab,kw OR systematic lymph node
	dissection:ti,ab,kw OR selective lymph node dissection:ti,ab,kw OR
	LND:ti,ab,kw OR LNS:ti,ab,kw
#4	randomly:ti,ab,kw OR randomlzed:ti,ab,kw OR RCT:ti,ab,kw OR
	trials:ti,ab,kw OR cohort:ti,ab,kw OR longitudinal:ti,ab,kw OR
	prospective:ti,ab,kw OK survival:ti,ab,kw

#5	#1 AND #2 AND #3 AND #4

4. Web of Science

Number	Search terms
#1	TS=(Non-Small-Cell OR Non-Small-Cell Lung Carcinomas OR Non-
	Small Cell Lung Cancer OR Non-Small-Cell Lung Carcinoma OR Non-
	Small Cell Lung Carcinoma OR Non-Small Cell Lung OR Non-Small Cell
	Lung Cancer OR Lung Neoplasms OR Pulmonary Neoplasms OR Lung
	Neoplasm OR Pulmonary Neoplasm OR Lung Cancer OR Lung Cancers
	OR Pulmonary Cancer OR Pulmonary Cancers OR Cancer of the Lung
	OR Cancer of Lung OR Non-Small-Cell Lung OR Lung Carcinoma OR
	Non-Small-Cell OR Lung Carcinomas OR NSCLC)
#2	TS=(Surgical Procedures OR Operative OR surgery OR surgery OR
	surgical OR operative OR postoperative)
#3	TS=(lymphadenectomy OR lymphadenectomy OR complete mediastinal
	lymphadenectomy OR mediastinal lymph node excision OR lobe-specific
	lymph node dissection OR mediastinal lymph node dissection OR
	mediastinal lymph node sampling OR lymph node dissection OR lymph
	node OR dissect OR sample OR selective mediastinal lymphadenectomy
	OR systematic lymph node dissection OR selective lymph node dissection
	OR LND OR LNS)
#4	TS=(randomly OR randomized OR RCT OR trials OR cohort OR
	longitudinal OR prospective OR survival)
#5	#1 AND #2 AND #3 AND #4

5. China National Knowledge Infrastructure (CNKI) (Chinese)

Search terms
(主题:"非小细胞肺癌" or "肺癌") and (主题:"淋巴结清扫方式" or "系统性
淋巴结清扫" or "选择性淋巴结清扫" or "叶特异性淋巴结清扫" or "纵膈淋巴
结清扫" or "纵膈淋巴结采样") and (全部: "随机对照试验")

6. WANFANG DATA (Chinese)

Search terms
(主题:"非小细胞肺癌" or "肺癌") and (主题:"淋巴结清扫方式" or "系统性
淋巴结清扫" or "选择性淋巴结清扫" or "叶特异性淋巴结清扫" or "纵膈淋巴
结清扫"or"纵膈淋巴结采样") and (全部:"随机对照试验")

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies

7. Chinese biomedical literature service system (Sinomed) (Chinese)

Search terms ("非小细胞肺癌" [常用字段:智能] OR "肺癌" [常用字段:智能]) AND ("肺癌"[常 用字段:智能]) AND ("随机对照试验"[常用字段:智能]) AND ("淋巴结清扫方式 "[全部字段:智能] OR "系统性淋巴结清扫"[全部字段:智能]OR "选择性淋巴结 清扫"[全部字段:智能] OR "叶特异性淋巴结清扫"[全部字段:智能] OR "纵膈淋 巴结采样"[全部字段:智能])

8. VIP database (Chinese)

Search terms
(主题:"非小细胞肺癌" or "肺癌") and (主题:"淋巴结清扫方式" or "系统性
淋巴结清扫" or "选择性淋巴结清扫" or "叶特异性淋巴结清扫" or "纵膈淋巴
结清扫"or"纵膈淋巴结采样") and (全部:"随机对照试验")

First author	
Country, year	
Sample size (males/females)	
Median age, y (range)	
Design	
Include or exclude	
Reason(s) for exclusion	
Follow-up (mean and range) (months)	
Tumor location	
Tumor size(cm)	
Tumor stage	
Surgery procedure	
Adjuvant treatment	
Primary outcomes:	
1. Overall recurrence rate	
2. Local recurrence rate (ipsilateral	
lung, ipsilateral pleura, trachea, etc.)	
3. Distant metastasis rate (contralateral	
lung, contralateral pleura, bone, liver, etc.)	
Second outcomes:	
1. Regional recurrence rate	
2. Lymph node metastasis rate	

PRISMA-P (Pre address in a syste	ferred emati	ا Reporting Items for Systematic review and Meta-Analysis Protocols) 2015 caecy c review protocol*	items to
Section and topic	Item No	Checklist item	Reported or Page #
ADMINISTRATIVI	E INF(DRMATION	0
Title:		at the second seco	
Identification	1a	Identify the report as a protocol of a systematic review	P1
Update	1b	If the protocol is for an update of a previous systematic review, identify as such	N/A
Registration	2	If registered, provide the name of the registry (such as PROSPERO) and registration number	P2
Authors:			
Contact	3a	Provide name, institutional affiliation, e-mail address of all protocol authors; provide physical mathematical difference of corresponding author	P1
Contributions	3b	Describe contributions of protocol authors and identify the guarantor of the review	P10
Amendments	4	If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments	N/A
Support:			
Sources	5a	Indicate sources of financial or other support for the review	N/A
Sponsor	5b	Provide name for the review funder and/or sponsor	N/A
Role of sponsor or funder	5c	Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol	N/A
INTRODUCTION			
Rationale	6	Describe the rationale for the review in the context of what is already known	P3-4
Objectives	7	Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO)	P4-5
METHODS		gies	
Eligibility criteria	8	Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as years considered, language, publication status) to be used as criteria for eligibility for the review	P4-5
Information sources	9	Describe all intended information sources (such as electronic databases, contact with study authors, trail registers or other grey literature sources) with planned dates of coverage	P5
Search strategy	10	Present draft of search strategy to be used for at least one electronic database, including planned limit such that it could be repeated	P5

25			BMJ Open by copen	
			2024-08 /right, in	
;	Study records:			
	Data management	11a	Describe the mechanism(s) that will be used to manage records and data throughout the review $ding f$	P6
	Selection process	11b	State the process that will be used for selecting studies (such as two independent reviewers) through each phase of the review (that is, screening, eligibility and inclusion in meta-analysis)	P6
	Data collection process	11c	Describe planned method of extracting data from reports (such as piloting forms, done independently in duplicate), any processes for obtaining and confirming data from investigators	P6
]	Data items	12	List and define all variables for which data will be sought (such as PICO items, funding sources) any pre-planned data assumptions and simplifications	P6
- (1	Outcomes and prioritization	13	List and define all outcomes for which data will be sought, including prioritization of main and a definitional outcomes, with rationale	P5
<u> </u> 	Risk of bias in individual studies	14	Describe anticipated methods for assessing risk of bias of individual studies, including whether the base of the outcome or study level, or both; state how this information will be used in data synthesis	P6-7
]	Data synthesis	15a	Describe criteria under which study data will be quantitatively synthesised	P7-8
		15b	If data are appropriate for quantitative synthesis, describe planned summary measures, methods of combining data from studies, including any planned exploration of consistency (such as I ² , Kendal's s)	P7-8
		15c	Describe any proposed additional analyses (such as sensitivity or subgroup analyses, meta-regression)	P8-9
		15d	If quantitative synthesis is not appropriate, describe the type of summary planned	P8
]	Meta-bias(es)	16	Specify any planned assessment of meta-bias(es) (such as publication bias across studies, selective reporting within studies)	P8
	Confidence in cumulative evidence	17	Describe how the strength of the body of evidence will be assessed (such as GRADE)	Р9
]	* It is strongly recom clarification on the it PRISMA-P Group a <i>From: Shamseer L, M</i>	imend tems. 1 nd is o toher 1	led that this checklist be read in conjunction with the PRISMA-P Explanation and Elaboratigen (gete when available) for im Amendments to a review protocol should be tracked and dated. The copyright for PRISMA-P. (including checklist) is held distributed under a Creative Commons Attribution Licence 4.0.	portant by the c review and
j	meta-analysis protoco	ols (PR	RISMA-P) 2015: elaboration and explanation. BMJ. 2015 Jan 2;349(jan02 1):g7647.	
			I Cê	
			Sio Sio	
			gra gra	
			e	
			<u> </u>	
			For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

BMJ Open

Protocol for a systematic review and meta-analysis of recurrence and metastasis of different surgical techniques for non-small cell lung cancer

Journal:	BMJ Open
Manuscript ID	bmjopen-2024-086503.R2
Article Type:	Protocol
Date Submitted by the Author:	31-Jul-2024
Complete List of Authors:	Huang, Xiongfeng; Fuzhou Medical College, Nanchang University Zhu, Donghong; The Ninth Hospital of Nanchang, Department of Respiratory Cao, Yaoxing; Jiangxi College of Traditional Chinese Medicine Li, Weijuan; Fuzhou Medical College, Nanchang University Lai, Jinxing; Affiliated Ganzhou Hospital of Nanchang University Ren, Yuxi; Jiangxi University of Traditional Chinese Medicine
Primary Subject Heading :	Surgery
Secondary Subject Heading:	Oncology
Keywords:	Lung Diseases, ONCOLOGY, SURGERY, Meta-Analysis



2

3

cancer

BMJ Open

Protocol for a systematic review and meta-analysis of recurrence and

metastasis of different surgical techniques for non-small cell lung

1		
2		
3		
4		
5		
6		
/		
8		
9		
10		
12		
13		
14		
15		
16		
17		
18		
19		
20		
21		
22		
25 24		
24		
25		
27		
28		
29		
30		
31		
32		
33		
34		
35		
36		
3/		
20		
39 40		
40		
42		
43		
44		
45		
46		
47		
48		
49		
50		
כן בט		
52 52		
55 54		
55		
56		
57		
58		
59		
60		

4	Xiongfeng Huang ¹ , Donghong Zhu ² , Yaoxing Cao ³ , Weijuan Li ¹ , Jinxing Lai ⁴ , Yuxi
5	Ren ⁵ *
6	1. Fuzhou Medical College, Nanchang University, Fuzhou, China.
7	2. Department of Respiratory, The Ninth Hospital of Nanchang, Nanchang, China.
8	3. Jiangxi College of Traditional Chinese Medicine, Fuzhou, China.
9	4. Affiliated Ganzhou Hospital of Nanchang University, Ganzhou, China.
10	5. Jiangxi University of Traditional Chinese Medicine, Nanchang, China.
11	*Correspondence: Yuxi Ren. E-mail: renyuxi009@163.com
12	
13	ABSTRACT
14	Introduction
15	Lung cancer remains the primary cause of cancer-related deaths on a global scale.
16	Surgery is the main therapeutic option for non-small cell lung cancer (NSCLC).
17	However, the optimal surgical approach for lymph node assessment in NSCLC
18	resection remains controversial, and it's still uncertain whether lymph node dissection
19	(LND) is more effective in reducing recurrence and metastasis rates in NSCLC
20	compared to lymph node sampling (LNS). Therefore, we will conduct a meta-analysis
21	to evaluate the recurrence and metastasis of LND versus LNS in patients with NSCLC.
22	Methods and analysis
23	This systematic review and meta-analysis will follow the Preferred Reporting Items for
24	Systematic Reviews and Meta-Analysis: The PRISMA Statement. According to the
25	predefined inclusion criteria, we will conduct a comprehensive search for randomized
26	controlled trials (RCTs) and non-randomized studies examining the recurrence and
27	metastasis of LND compared to LNS in patients with NSCLC. A literature search from
28	inception in PubMed, EMBASE, the Cochrane Library, CNKI, WanFang, Sinomed,
29	VIP, and Web of Science. There will be no limitations on language, and the search will $$^{\rm 1}$$
	For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Yuxi

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

BMJ Open

3 ⊿
4 5
5
7
, 8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
20
27
20
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
4/ 10
40 40
+9 50
51
52
53
54
55
56
57
58
59
60

1 2

be undertaken on 30 August 2024 with regular search for new studies. Additionally, 30 relevant literature references will be retrieved and hand searching of pertinent journals 31 32 will be conducted. The main outcomes include overall recurrence rate, local recurrence rate, and distant metastasis rate. The supplementary outcomes encompass the rates of 33 regional recurrence and lymph node metastasis. Two independent reviewers will 34 perform screening, data extraction, and quality assessment. Our reviewers will perform 35 subgroup analysis, sensitivity analysis, and publication bias analysis to evaluate the 36 heterogeneity and robustness. Review Manager 5.4 will be applied in analyzing and 37 synthesizing. The Grading of Recommendations Assessment, Development and 38 Evaluation (GRADE) will be used to assess the quality of evidence for the whole study. 39 **Ethics and dissemination** 40

Ethical approval is dispensable for this study since no private information of the
participants will be involved. The findings of the present study will be disseminated
through a peer-reviewed journal or conference presentation.

44 Study registration

45 The protocol of the systematic review has been registered on Open Science Framework,

46 with a registration DOI https://doi.org/10.17605/OSF.IO/S2FT5.

47 STRENGTHS AND LIMITATIONS OF THIS STUDY

- 48 > The Grading of Recommendations Assessment, Development, and Evaluation
 49 (GRADE) system will be utilized to evaluate the quality of the evidence.
- To minimize the risk of bias, two researchers will independently carry out the study
 selection, data extraction, and quality assessment.
- Non-randomized studies may introduce methodological limitations and affect the
 overall quality of evidence.
- The potential existence of significant heterogeneity among various studies could
 hinder the derivation of causal conclusions from their combined findings.
- Because our search will focus primarily on English and Chinese databases, there is
 a possibility of overlooking studies in other languages, which could result in
 language bias.

INTRODUCTION

Non-small cell lung cancer (NSCLC), the predominant form of lung malignancy, continues to pose a significant threat to global health. In 2024, the American Cancer Society estimated that lung cancer is the leading cause of cancer death, with an estimated 340 people dying from lung cancer every day, almost 2.5 times more than colorectal cancer, which ranks second in cancer deaths.[1] Lung cancer remains the primary cause of cancer-related deaths on a global scale.[2-5]

Surgical resection plays a crucial role in the management of NSCLC, and lymph node staging is essential for accurate prognostication and treatment planning. Lymph node dissection (LND) and lymph node sampling (LNS) are two surgical techniques used for NSCLC, but their relative effectiveness remains controversial.[6-15] LNS involves the removal of a smaller number of lymph nodes for pathological examination. This approach is generally less invasive, leading to shorter operative times and potentially fewer postoperative complications.[16] However, it may not provide as comprehensive nodal staging as dissection, leading to potential underestimation of the disease stage. LND, conversely, involves the complete removal of lymph nodes and surrounding tissue in specific anatomic regions. This approach offers a comprehensive assessment of nodal involvement, allowing for more accurate staging and potentially improving long-term outcomes. However, it is a more invasive procedure that may increase the risk of post-operative complications, which may result in a reduction in postoperative quality of life for patients. Furthermore, for some patients with early NSCLC, the incidence of lymph node metastasis is not very high, and most patients may not have regional lymph node metastasis. Thus, the necessity of performing complete and systematic lymph node dissection in patients with NSCLC and whether the expected clinical effect can be achieved remains controversial.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies

Patients with NSCLC continue to experience a notable rate of recurrence and metastasis following surgical intervention, thereby impacting their overall survival outcomes. A meta-analysis of 11 observational studies showed that surgery decreased the risk of NSCLC recurrence in stage I–IV. [17] And several studies have compared

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

the recurrence and metastasis of LND and LNS in NSCLC surgery. Based on three previous studies, [18-20] LND has been shown to reduce the incidence of recurrence and metastasis in NSCLC. And Meng et al. [21] have posited in their meta-analysis that the use of LND may be effective in eliminating hidden micrometastases to reduce the risk of both local recurrence and distant metastases. However, the results of our previous meta-analysis indicated that in individuals with NSCLC, LND and LNS yielded similar rates of recurrence and metastasis.[22] Additionally, other studies have also shown that lymph node dissection conducted in lung cancer does not impact the occurrence of recurrence and metastasis.[23-25]

The optimal surgical approach for lymph node assessment in NSCLC resection remains controversial, and it's still uncertain whether LND is more effective in reducing recurrence and metastasis rates in NSCLC compared to LNS. Clearly, newer systematic review and meta-analyses are required to resolve this issue, and definitive analyses can provide stronger rationales for the choice of a specific therapy. Consequently, we will perform a meta-analysis of relevant randomized controlled trials (RCTs) and non-randomized studies to evaluate the recurrence and metastasis of LND versus LNS in NSCLC patients. We hope this meta-analysis will offer strong evidence for the surgical treatment of patients with NSCLC and guide future clinical practice.

107 MATERIALS AND METHODS

108 Registration and reporting

This review protocol has been officially registered in the Open Science Framework (OSF) database (DOI https://doi.org/10.17605/OSF.IO/S2FT5). The checklist for the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) can be found in Supplemental File 1. [26] If there is a change to this protocol, details of the amendment and the reasons for it will be added to OSF. The systematic review and meta-analysis is anticipated to commence on August 30th and conclude on December 30th.

59 117 Eligibility criteria

Types of studies

All relevant published RCTs and non-randomized studies will be included. The review
will not include certain types of studies, such as methodological papers, editorials,
qualitative research, individual case reports, and secondary studies like narrative
reviews, systematic reviews and meta-analyses. There will be no restrictions on the
language used or the time of publication.

Types of participants

125 Individuals with NSCLC who received either LND or LNS will be eligible for inclusion,

126 with no limitations based on country, race, ethnicity, age, gender, or occupation.

Type of outcomes

The main outcomes are as follows: overall recurrence rate, local recurrence rate (ipsilateral lung, ipsilateral pleura, trachea, etc.), and distant metastasis rate (contralateral lung, contralateral pleura, bone, liver, etc.). The supplementary outcomes encompass the rates of regional recurrence and lymph node metastasis. Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

132 Inf

2 Information source and search strategy

A literature search from inception in PubMed, EMBASE, the Cochrane Library, CNKI, WanFang, Sinomed, VIP, and Web of Science. The Gray Journal includes annual meetings of the American Society of Clinical Oncology and the American Society of Thoracic Surgery (chest surgery), using combinations of the search terms: lymph node dissection, LND, lymph node sampling, LNS, and non-small cell lung cancer, NSCLC. Detailed search strategies are shown in supplemental File 2. There will be no limitations on language, and the search will be undertaken on 30 August 2024 with regular search for new studies. The bibliography of all articles obtained will be examined to identify additional publications that may be pertinent. In addition, abstracts from the American Society of Clinical Oncology and the European Society of Medical Oncology will be searched for potential studies. In order to gather thorough information from qualifying studies, we will contact primary authors to request any pertinent data, such as supplementary materials that may not have been fully disclosed or reported, and information from informal sources related to the research. Two reviewers will examine the reference list and individually choose the studies.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Study Selection

The chosen articles will undergo a dual review process by two separate authors. Following the initial screening of titles and abstracts of papers found through the search strategy, the papers will be sorted into two categories: potentially relevant or not relevant based on the eligibility criteria. Subsequently, efforts will be made to obtain the full texts of all potentially relevant papers, which will then be reviewed against the eligibility criteria. In the event of disagreements during the full-text screening, they will be resolved through discussion. If a consensus cannot be reached, a third author will step in to settle the dispute. The study selection process is illustrated in Figure 1.

Data extraction process

The data will be taken from each full-text article that meets the eligibility criteria: study design; country of study; interventions; outcomes; number and general characteristics of participants, for example, age, and gender. The process of data extraction will be conducted by two reviewers, with Microsoft Excel being employed as the tool for data collection. Any disagreements between the two reviewers will be resolved by discussion or by consulting with the third reviewer, the characteristics of the study are attached as Supplemental File 3.

Dealing with missing data

In cases where data is unavailable, two reviewers will make efforts to contact the original authors via email or phone to request supplementary information. Should the data remain unattainable, the study will be omitted from the analysis. The potential influence of missing data on the comprehensive analysis will be evaluated through sensitivity analysis.

Study risk of bias assessment

Two reviewers will assess the quality of the included studies. Disagreement between the two reviewers will be resolved by discussion with the third reviewer.

We will evaluate the included RCTs' quality using the Cochrane Handbook's "risk of bias" technique.[27] Sequence generation, allocation concealment, blinding, incomplete data, and selective reporting were assessed, and each of them was graded as "yes(+)", "no(-)" or "unclear(?)", which reflected low risk of bias, high risk of bias,

and uncertain risk of bias, respectively.[28] The Newcastle-Ottawa scale will be used to evaluate the methodological rigor of non-randomized studies. The Newcastle-Ottawa Scale consists of eight items that are divided into three categories: selection (four items, one star each), comparability (one item, up to two stars), and exposure/outcome (three items, one star each).[29] One star will be given for each item in the selection and outcome domains, and up to two stars will be given for the comparability domain, when a primary study satisfies the methodological required standard. Studies with star values between 0 and 4 will ultimately be classified as having a high risk of bias, studies with scores between 5 and 6 as having a moderate risk of bias, and studies with scores between 7 and 9 as having a low risk of bias.[30]

Patient and public involvement

Since this study will focus on reviewing existing literature, there will be no direct participation of patients or the public. While patients will not be engaged in data collection or analysis for this review, their input, along with that of the public, will be considered in shaping future research stemming from this study.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

DATA ANALYSIS

Statistical analysis

Meta-analysis will be planned with sufficient clinically and statistically homogeneous and comparable reported outcomes among studies by pooling data using Review Manager V.5.4 software by The Cochrane Collaboration. Dichotomous data will be compared using a risk ratio (RR) or odds ratio (OR). Respective 95% confidence intervals (CI) will be calculated for each estimate and presented in forest plots.

Statistical heterogeneity will be assessed visually by Q and I^2 statistics.[31] For the Q statistic, a *P* value<0.10 Will be regarded as statistically significant for heterogeneity. For the I^2 statistic, [32] if there is heterogeneity among the study results ($I^2 > 50\%$), the heterogeneity source will be further examined. After the exclusion of effects exerted by significant clinical heterogeneity, the random-effects model will be employed for the meta-analysis. [33, 34] If there is no heterogeneity between the study results ($I^2 < 50\%$), this study will use the fixed-effect model in terms of meta-analysis.[35, 36] All reported

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

P-values are 2-sided and values of P < 0.05 will be regarded as significant for all included studies. In cases of significant heterogeneity encountered during the meta-analysis procedure, several strategies will be implemented. Firstly, a subgroup analysis will be conducted to classify studies according to potential sources of heterogeneity, leading to separate meta-analyses for each subgroup. Secondly, meta-regression techniques will be employed to examine study attributes and pinpoint factors that may be influencing the observed heterogeneity. Lastly, if challenges with high heterogeneity persist, the option of transforming the meta-analysis into a systematic review will be considered, allowing for a qualitative synthesis of studies without quantitative amalgamation.

217 Assessment of publication bias

The funnel plot will be used to assess reporting bias. A symmetrical funnel shape will suggest the absence of publication bias, whereas an asymmetrical funnel plot will indicate the presence of such bias. An objective assessment of publication bias will be conducted employing Egger's linear regression test, where a p-value less than 0.1 is considered statistically significant, indicating the presence of publication bias.[37, 38] And we will conduct a trim and fill analysis to address any potential publication bias. This method involves excluding outlier studies and estimating hypothetical missing studies to create a balanced funnel plot.

226 Subg

5 Subgroup and sensitivity analyses

Subgroup analyses will be conducted based on study and population variables, including study type, age, gender, intervention approaches, sample size, and other factors. For sensitivity analysis, studies of poorer methodological quality will be removed to see if their deletion alters the outcomes of the analyses. In particular, we will exclude non-randomized studies deemed to be of low quality (rated between 0 and 4 stars) and those RCTs identified as having a high risk of bias. This methodology will enable us to evaluate the reliability of our findings and pinpoint any potential sources of bias. When heterogeneity is substantial, the leave-one-out method is employed to ascertain whether it arises from a specific study. For instance, to ascertain whether

Page 9 of 25

BMJ Open

heterogeneity diminishes, we eliminate one study. This approach is employed to investigate each study individually, in order to identify the root cause of heterogeneity.

238 Grading the quality of evidence

The evaluation of the evidence's quality throughout the entire study will be conducted utilizing the GRADE (Grading of Recommendations Assessment, Development and Evaluation) framework.[39-41] This system is frequently employed to evaluate the credibility of evidence and determine the level of recommendations. Two independent reviewers will employ the five GRADE considerations, including the risk of bias, consistency of effect, imprecision, indirectness, and publication bias, to meticulously evaluate the certainty of the evidence and arrive at sound conclusions.[42, 43] Verification will be carried out upon completion, and any uncertainties will be deliberated among reviewers or escalated to a third expert for guidance.

The level of evidence will be assessed and categorized as high, moderate, low, or very low. RCT evidence is initially considered to have a high level of certainty, but this evaluation may be adjusted downwards if factors such as risk of bias, indirectness, inconsistency, imprecision, and publication bias are identified. On the other hand, evidence from observational studies is typically assigned a low level of certainty, but this rating may be elevated if there is evidence for a large magnitude of effect, mitigation of potential bias or confounding factors, leading to an upgrade from the initial low rating. Strong recommendations are made when there is a high level of evidence, while practice considerations are given when there is a moderate level of evidence. When the evidence level is below moderate, it is stated that there is insufficient evidence from scientific literature to provide guidance to policymakers, clinicians, and patients.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

260 Updates to study protocol

If modifications to the review protocol are deemed necessary, these adjustments will be
thoroughly documented and incorporated as supplementary material alongside the final
manuscript. Additionally, these updates will be reflected on the OSF register for future
reference.

265 Ethics and dissemination

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

BMJ Open

Ethical approval is dispensable for this study since no private information of the
participants will be involved. The findings of the present study will be disseminated
through a peer-reviewed journal or conference presentation.

269 Author contributions

XH conceived the study. XH and YC registered the protocol. XH and WL drafted the
protocol. YC and JL revised it. XH and YR developed the search strategies and will run
them. XH and YR will select studies and extract data. XH and DZ will analyze the data.
All authors contributed to the article and approved the submitted version. XH is the
guarantor.

275 Funding

Science and technology project of Fuzhou Medical College of Nanchang University
(fykj202404); Science and technology project of Jiangxi Provincial Administration of
Traditional Chinese Medicine (2023A0289); Science and technology project of Jiangxi
Provincial Administration of Traditional Chinese Medicine (2022B1103); Jiangxi
Province key research and development program (2020YBBGWL001), Jiangxi
Provincial Department of Education Science and Technology research key project
(GJJ208902).

- **Competing interests**
- 284 The authors declare no conflict of interest.
 - 285 Word count
 - 286 2314 words

REFERENCES

- 289 1. Siegel RL, Giaquinto AN. Cancer statistics, 2024. *CA: a cancer journal for clinicians*290 2024;74(1):12-49. doi: 10.3322/caac.21820
- 291 2. Bade BC, Dela Cruz CS. Lung Cancer 2020: Epidemiology, Etiology, and Prevention. *Clinics in* 292 *chest medicine* 2020;41(1):1-24. doi: 10.1016/j.ccm.2019.10.001 [published Online First:
 293 2020/02/06]
- 294 3. Herbst RS, Heymach JV, Lippman SM. Lung cancer. The New England journal of medicine

BMJ Open

2 3		
4 5	295	2008;359(13):1367-80. doi: 10.1056/NEJMra0802714 [published Online First: 2008/09/26]
6 7	296	4. Gridelli C, Rossi A, Maione P, et al. Vaccines for the treatment of non-small cell lung cancer: a
8	297	renewed anticancer strategy. The oncologist 2009;14(9):909-20. doi:
9 10	298	10.1634/theoncologist.2009-0017 [published Online First: 2009/09/04]
11 12	299	5. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA: a cancer journal for clinicians
13 14	300	2011;61(2):69-90. doi: 10.3322/caac.20107 [published Online First: 2011/02/08]
15 16	301	6. Xu J, Lai J, Huang X. Survival outcomes following complete mediastinal lymphadenectomy or
17 18	302	selective mediastinal lymphadenectomy in patients with stage I-IIIA non-small cell lung cancer:
19 20	303	protocol for a systematic review and meta-analysis. BMJ Open 2024;14(3):e084520. doi:
20 21 22	304	10.1136/bmjopen-2024-084520
22 23 24	305	7. Zhang Y, Deng C, Zheng Q, et al. Selective Mediastinal Lymph Node Dissection Strategy for
24 25 26	306	Clinical T1N0 Invasive Lung Cancer: A Prospective, Multicenter, Clinical Trial. Journal of
20	307	thoracic oncology : official publication of the International Association for the Study of Lung
28 29	308	Cancer 2023;18(7):931-39. doi: 10.1016/j.jtho.2023.02.010 [published Online First:
30 31	309	2023/02/26]
32 33	310	8. Wang Y, Darling GE. Complete mediastinal lymph node dissection versus systematic lymph node
34 35	311	sampling in surgical treatment of non-small cell lung cancer: do we have the answer? Journal
36 37	312	of thoracic disease 2017;9(11):4169-70. doi: 10.21037/jtd.2017.10.39 [published Online First:
38 39	313	2017/12/23]
40 41	314	9. Xu F, Qi L, Yue D, et al. The effect of the extent of lymph node dissection for stage IA non-
42 43	315	small-cell lung cancer on patient disease-free survival. Clinical lung cancer 2013;14(2):181-7.
44 45	316	doi: 10.1016/j.cllc.2012.09.002 [published Online First: 2012/12/01]
46 47	317	10. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the
48 49	318	published literature for survival endpoints. Statistics in medicine 1998;17(24):2815-34. doi:
50 51	319	10.1002/(sici)1097-0258(19981230)17:24<2815::aid-sim110>3.0.co;2-8 [published Online
52 53	320	First: 1999/01/28]
54 55	321	11. Ou SH, Zell JA. Prognostic significance of the number of lymph nodes removed at lobectomy
56 57	322	in stage IA non-small cell lung cancer. Journal of thoracic oncology : official publication of the
58 59	323	International Association for the Study of Lung Cancer 2008;3(8):880-6. doi:
60	324	10.1097/JTO.0b013e31817dfced [published Online First: 2008/08/02] 11

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

325 12. Wang Z, Qi Z, Cheng D, et al. Lobe-Specific Node Dissection Can Be a Suitable Alternative to
326 Systematic Lymph Node Dissection in Highly Selective Early-Stage Non-Small-Cell Lung
327 Cancer Patients: A Meta-Analysis. *Annals of thoracic and cardiovascular surgery : official*328 *journal of the Association of Thoracic and Cardiovascular Surgeons of Asia* 2021;27(3):143-

13. Tantraworasin A, Saeteng S, Siwachat S, et al. Impact of lymph node management on resectable
non-small cell lung cancer patients. *Journal of thoracic disease* 2017;9(3):666-74. doi:
10.21037/jtd.2017.02.90 [published Online First: 2017/04/30]

50. doi: 10.5761/atcs.oa.20-00136 [published Online First: 2020/12/08]

- 14. Yang M, Cao H, Guo X, et al. The number of resected lymph nodes (nLNs) combined with
 tumor size as a prognostic factor in patients with pathologic N0 and Nx non-small cell lung
 cancer. *PloS one* 2013;8(9):e73220. doi: 10.1371/journal.pone.0073220 [published Online First:
 2013/09/12]
- 337 15. Wang W, Chen D, Xi K, et al. Impact of Different Types of Lymphadenectomy Combined With
 338 Different Extents of Tumor Resection on Survival Outcomes of Stage I Non-small-cell Lung
 339 Cancer: A Large-Cohort Real-World Study. *Frontiers in oncology* 2019;9:642. doi:
 340 10.3389/fonc.2019.00642 [published Online First: 2019/08/10]
- 341 16. Dezube AR, Mazzola E, Bravo-Iñiguez CE, et al. Analysis of Lymph Node Sampling Minimums
 342 in Early Stage Non-Small-Cell Lung Cancer. *Seminars in thoracic and cardiovascular surgery* 343 2021;33(3):834-45. doi: 10.1053/j.semtcvs.2020.11.007 [published Online First: 2020/11/13]
- 344 17. Hu J, Miao H, Li R, et al. Surgery and subsequent risk of non-small cell lung cancer recurrence:
 345 a meta-analysis of observational studies. *Translational cancer research* 2020;9(3):1960-68. doi:
 346 10.21037/tcr.2020.02.15
 - 347 18. Wu Y, Huang ZF, Wang SY, et al. A randomized trial of systematic nodal dissection in
 348 resectable non-small cell lung cancer. *Lung cancer (Amsterdam, Netherlands)* 2002;36(1):1-6.
 349 doi: 10.1016/s0169-5002(01)00445-7 [published Online First: 2002/03/14]
 - 350 19. Su X, Wang X, Long H, et al. Mediastinal lymph node dissection affects survival in patients
 351 with stage I non-small cell lung cancer. *The Thoracic and cardiovascular surgeon*352 2008;56(4):226-30. doi: 10.1055/s-2007-989494 [published Online First: 2008/05/16]
- 353 20. Lardinois D, Suter H, Hakki H, et al. Morbidity, survival, and site of recurrence after mediastinal
 - 354 lymph-node dissection versus systematic sampling after complete resection for non-small cell12

BMJ Open

355	lung cancer. The Annals of thoracic surgery 2005;80(1):268-74; discussion 74-5. doi:
356	10.1016/j.athoracsur.2005.02.005 [published Online First: 2005/06/25]
357	21. Meng D, Zhou Z, Wang Y, et al. Lymphadenectomy for clinical early-stage non-small-cell lung
358	cancer: a systematic review and meta-analysis. European journal of cardio-thoracic surgery :
359	official journal of the European Association for Cardio-thoracic Surgery 2016;50(4):597-604.
360	doi: 10.1093/ejcts/ezw083 [published Online First: 2016/04/24]
361	22. Huang X, Wang J, Chen Q, et al. Mediastinal lymph node dissection versus mediastinal lymph
362	node sampling for early stage non-small cell lung cancer: a systematic review and meta-analysis.
363	PloS one 2014;9(10):e109979. doi: 10.1371/journal.pone.0109979 [published Online First:
364	2014/10/09]
365	23. Mokhles S, Macbeth F, Treasure T, et al. Systematic lymphadenectomy versus sampling of
366	ipsilateral mediastinal lymph-nodes during lobectomy for non-small-cell lung cancer: a
367	systematic review of randomized trials and a meta-analysis. European journal of cardio-
368	thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
369	2017;51(6):1149-56. doi: 10.1093/ejcts/ezw439 [published Online First: 2017/02/06]
370	24. Luo J, Yang S, Dong S. Selective Mediastinal Lymphadenectomy or Complete Mediastinal
371	Lymphadenectomy for Clinical Stage I Non-Small Cell Lung Cancer: A Meta-Analysis.
372	2021;38(12):5671-83. doi: 10.1007/s12325-021-01954-w
373	25. Darling GE, Allen MS, Decker PA, et al. Randomized trial of mediastinal lymph node sampling
374	versus complete lymphadenectomy during pulmonary resection in the patient with N0 or N1
375	(less than hilar) non-small cell carcinoma: results of the American College of Surgery Oncology
376	Group Z0030 Trial. The Journal of thoracic and cardiovascular surgery 2011;141(3):662-70.
377	doi: 10.1016/j.jtcvs.2010.11.008 [published Online First: 2011/02/22]
378	26. Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and
379	meta-analysis protocols (PRISMA-P) 2015 statement. Systematic reviews 2015;4(1):1. doi:
380	10.1186/2046-4053-4-1 [published Online First: 2015/01/03]
381	27. Higgins JP, Thomas J, Chandler J, et al. Cochrane Handbook for Systematic Reviews of
382	Interventions version 6.4 (updated August 2023). Cochrane 2023
383	28. Higgins JP, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration's tool for assessing
384	risk of bias in randomised trials. <i>BMJ (Clinical research ed)</i> 2011;343:d5928. doi: 13

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

BMJ Open



BMJ Open

2		
3 4	415	Gesundheitswesen 2013;107(9-10):646-64. doi: 10.1016/j.zefq.2013.10.034 [published Online
5 6	416	First: 2013/12/10]
7 8	417	40. Guyatt GH, Oxman AD, Kunz R, et al. What is "quality of evidence" and why is it important to
9 10	418	clinicians? BMJ (Clinical research ed) 2008;336(7651):995-8. doi:
11 12	419	10.1136/bmj.39490.551019.BE [published Online First: 2008/05/06]
13 14	420	41. Guyatt GH, Oxman AD, Kunz R, et al. GRADE guidelines: 2. Framing the question and deciding
15 16	421	on important outcomes. Journal of clinical epidemiology 2011;64(4):395-400. doi:
17 18	422	10.1016/j.jclinepi.2010.09.012 [published Online First: 2011/01/05]
19 20	423	42. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of
21 22	424	evidence and strength of recommendations. BMJ (Clinical research ed) 2008;336(7650):924-6.
23	425	doi: 10.1136/bmj.39489.470347.AD [published Online First: 2008/04/26]
25	426	43. H S, Brozek J, Oxman AE. GRADE handbook for grading quality of evidence and strength of
27	427	recommendation. 2009
20 29 20	428	
30 31 32	429	Appendices
33 34	430	Fig 1. Flow diagram showing the selection process of articles.
35 36	431	Supplemental File 1. PRISMA-P-checklist.
37 38	432	Supplemental File 2. Search strategy.
39 40	433	Supplemental File 3. General information of the included studies.
41 42		
43		
45		
46 47		
48		
49		
50 51		
52		
53		
54		
55 56		
57		
58		
59 60		

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

PRISMA 2020 flow diagram for new systematic reviews which included searches of databases and registers only



*Consider, if feasible to do so, reporting the number of records identified from each database or register searched (rather than the total number across all databases/registers).

**If automation tools were used, indicate how many records were excluded by a human and how many were excluded by automation tools.

From: Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71. doi: 10.1136/bmj.n71

For more information, visit: http://www.prisma-statement.org/

		copyrig
PRISMA-P (P address in a sy	referre stemati	d Reporting Items for Systematic review and Meta-Analysis Protocols) 2015 checklist: recommended ic review protocol*
Section and topic	Item No	Checklist item of 22
ADMINISTRAT	VE INF	
Title:		eligne at the second
Identification	1a	Identify the report as a protocol of a systematic review
Update	1b	If the protocol is for an update of a previous systematic review, identify as such
Registration	2	If registered, provide the name of the registry (such as PROSPERO) and registration number
Authors:		and
Contact	3a	Provide name, institutional affiliation, e-mail address of all protocol authors; provide physical main address of correspondiauthor
Contributions	3b	Describe contributions of protocol authors and identify the guarantor of the review
Amendments	4	If the protocol represents an amendment of a previously completed or published protocol, identified as such and list changes; otherwise, state plan for documenting important protocol amendments
Support:		
Sources	5a	Indicate sources of financial or other support for the review
Sponsor	5b	Provide name for the review funder and/or sponsor
Role of spons or funder	or 5c	Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol
INTRODUCTIO	N	
Rationale	6	Describe the rationale for the review in the context of what is already known
Objectives	7	Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO)
METHODS		gies
Eligibility criteria	8	Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as years considered, language, publication status) to be used as criteria for eligibility for the review
Information source	es 9	Describe all intended information sources (such as electronic databases, contact with study authors, trail registers or other gree literature sources) with planned dates of coverage
Search strategy	10	Present draft of search strategy to be used for at least one electronic database, including planned limit such that it could be repeated
		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

3

		BMJ Open by jo co ee	
		pyrig	
		ht, 14 , i - 08	
Study records:			
Data management	11a	Describe the mechanism(s) that will be used to manage records and data throughout the review $\begin{bmatrix} a & b \\ c & b \\ c & c \\ c & c$	P6
Selection process	11b	State the process that will be used for selecting studies (such as two independent reviewers) through each phase of the review (that is, screening, eligibility and inclusion in meta-analysis)	P6
Data collection process	11c	Describe planned method of extracting data from reports (such as piloting forms, done independed in the processes for obtaining and confirming data from investigators	P6
Data items	12	List and define all variables for which data will be sought (such as PICO items, funding sources) to be a sumption of the source	P6
Outcomes and rioritization	13	List and define all outcomes for which data will be sought, including prioritization of main and a definitional and a definition of main and a def	P5
Risk of bias in ndividual studies	14	Describe anticipated methods for assessing risk of bias of individual studies, including whether the study level, or both; state how this information will be used in data synthesis	P6-7
Data synthesis	15a	Describe criteria under which study data will be quantitatively synthesised	P7-8
	15b	If data are appropriate for quantitative synthesis, describe planned summary measures, methods of combining data from studies, including any planned exploration of consistency (such as I ² , Kendal's s)	P7-8
	15c	Describe any proposed additional analyses (such as sensitivity or subgroup analyses, meta-regresed on g	P8-9
	15d	If quantitative synthesis is not appropriate, describe the type of summary planned	P8
leta-bias(es)	16	Specify any planned assessment of meta-bias(es) (such as publication bias across studies, selectized regorting within studies)	P8
Confidence in umulative evidence	17	Describe how the strength of the body of evidence will be assessed (such as GRADE)	P9
It is strongly recon larification on the i PRISMA-P Group a From: Shamseer L, M neta-analysis protoco	amend tems. A and is d loher 1 pls (PR	Amendments to a review protocol should be tracked and dated. The copyright for PRISMA-P (including checklist) is held distributed under a Creative Commons Attribution Licence 4.0. D, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart L, PRISMA-P Group. Preferred reporting items for systemation (SIGMA-P) 2015: elaboration and explanation. BMJ. 2015 Jan 2;349(jan02 1):g7647.	iportant by the c review an
		gies.	
		1genc	
		e Bibliographic	
		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

Supplementary file 2. Search strategy

1. PubMed

Number	Search terms
#1	Non-Small-Cell OR Non-Small-Cell Lung Carcinomas OR Non-Small
	Cell Lung Cancer OR Non-Small-Cell Lung Carcinoma OR Non-Small
	Cell Lung Carcinoma OR Non-Small Cell Lung OR Non-Small Cell Lung
	Cancer OR Lung Neoplasms OR Pulmonary Neoplasms OR Lung
	Neoplasm OR Pulmonary Neoplasm OR Lung Cancer OR Lung Cancers
	OR Pulmonary Cancer OR Pulmonary Cancers OR Cancer of the Lung
	OR Cancer of Lung OR Non-Small-Cell Lung OR Lung Carcinoma OR
	Non-Small-Cell OR Lung Carcinomas OR NSCLC [Title/Abstract]
#2	Surgical Procedures OR Operative OR surgery OR surgery OR surgical
	OR operative OR postoperative [Title/Abstract]
#3	lymphadenectomy OR lymphadenectomy OR complete mediastinal
	lymphadenectomy OR mediastinal lymph node excision OR lobe-specific
	lymph node dissection OR mediastinal lymph node dissection OR
	mediastinal lymph node sampling OR lymph node dissection OR lymph
	node OR dissect OR sample OR selective mediastinal lymphadenectomy
	OR systematic lymph node dissection OR selective lymph node dissection
	OR LND OR LNS [Title/Abstract]
#4	randomly OR randomized OR RCT OR trials OR cohort OR longitudinal
	OR prospective OR survival [Title/Abstract]
#5	#1 AND #2 AND #3 AND #4 [Title/Abstract]
2. Embas	e O

2. Embase

Number	Search terms
#1	Non-Small-Cell:ti,ab,kw OR Non-Small-Cell Lung Carcinomas:ti,ab,kw
	OR Non-Small Cell Lung Cancer:ti,ab,kw OR Non-Small-Cell Lung
	Carcinoma:ti,ab,kw OR Non-Small Cell Lung Carcinoma:ti,ab,kw OR
	Non-Small Cell Lung:ti,ab,kw OR Non-Small Cell Lung Cancer:ti,ab,kw
	OR Lung Neoplasms:ti,ab,kw OR Pulmonary Neoplasms:ti,ab,kw OR
	Lung Neoplasm:ti,ab,kw OR Pulmonary Neoplasm:ti,ab,kw OR Lung
	Cancer:ti,ab,kw OR Lung Cancers:ti,ab,kw OR Pulmonary
	Cancer:ti,ab,kw OR Pulmonary Cancers:ti,ab,kw OR Cancer of the
	Lung:ti,ab,kw OR Cancer of Lung:ti,ab,kw OR Non-Small-Cell
	Lung:ti,ab,kw OR Lung Carcinoma:ti,ab,kw OR Non-Small-Cell:ti,ab,kw
	OR Lung Carcinomas:ti,ab,kw OR NSCLC:ti,ab,kw
#2	Surgical Procedures:ti,ab,kw OR Operative OR surgery:ti,ab,kw OR
	surgery:ti,ab,kw OR surgical:ti,ab,kw OR operative:ti,ab,kw OR
	postoperative:ti,ab,kw

#3	lymphadenectomy:ti,ab,kw OR lymphadenectomy:ti,ab,kw OR complete
	mediastinal lymphadenectomy:ti,ab,kw OR mediastinal lymph node
	excision:ti,ab,kw OR lobe-specific lymph node dissection:ti,ab,kw OR
	mediastinal lymph node dissection:ti,ab,kw OR mediastinal lymph node
	sampling:ti,ab,kw OR lymph node dissection:ti,ab,kw OR lymph
	node:ti,ab,kw OR dissect:ti,ab,kw OR sample:ti,ab,kw OR selective
	mediastinal lymphadenectomy:ti,ab,kw OR systematic lymph node
	dissection:ti,ab,kw OR selective lymph node dissection:ti,ab,kw OR
	LND:ti,ab,kw OR LNS:ti,ab,kw
#4	randomly:ti,ab,kw OR randomized:ti,ab,kw OR RCT:ti,ab,kw OR
	trials:ti,ab,kw OR cohort:ti,ab,kw OR longitudinal:ti,ab,kw OR
	prospective:ti,ab,kw OR survival:ti,ab,kw
#5	#1 AND #2 AND #3 AND #4

3. Cochrane Library

Number	Search terms
#1	Non-Small-Cell:ti,ab,kw OR Non-Small-Cell Lung Carcinomas:ti,ab,kw
	OR Non-Small Cell Lung Cancer:ti,ab,kw OR Non-Small-Cell Lung
	Carcinoma:ti,ab,kw OR Non-Small Cell Lung Carcinoma:ti,ab,kw OR
	Non-Small Cell Lung:ti,ab,kw OR Non-Small Cell Lung Cancer:ti,ab,kw
	OR Lung Neoplasms:ti,ab,kw OR Pulmonary Neoplasms:ti,ab,kw OR
	Lung Neoplasm:ti,ab,kw OR Pulmonary Neoplasm:ti,ab,kw OR Lung
	Cancer:ti,ab,kw OR Lung Cancers:ti,ab,kw OR Pulmonary
	Cancer:ti,ab,kw OR Pulmonary Cancers:ti,ab,kw OR Cancer of the
	Lung:ti,ab,kw OR Cancer of Lung:ti,ab,kw OR Non-Small-Cell
	Lung:ti,ab,kw OR Lung Carcinoma:ti,ab,kw OR Non-Small-Cell:ti,ab,kw
	OR Lung Carcinomas:ti,ab,kw OR NSCLC:ti,ab,kw
#2	Surgical Procedures:ti,ab,kw OR Operative OR surgery:ti,ab,kw OR
	surgery:ti,ab,kw OR surgical:ti,ab,kw OR operative:ti,ab,kw OR
	postoperative:ti,ab,kw
#3	lymphadenectomy:ti,ab,kw OR lymphadenectomy:ti,ab,kw OR complete
	mediastinal lymphadenectomy:ti,ab,kw OR mediastinal lymph node
	excision:ti,ab,kw OR lobe-specific lymph node dissection:ti,ab,kw OR
	mediastinal lymph node dissection:ti,ab,kw OR mediastinal lymph node
	sampling:ti,ab,kw OR lymph node dissection:ti,ab,kw OR lymph
	node:ti,ab,kw OR dissect:ti,ab,kw OR sample:ti,ab,kw OR selective
	mediastinal lymphadenectomy:ti,ab,kw OR systematic lymph node
	dissection:ti,ab,kw OR selective lymph node dissection:ti,ab,kw OR
	LND:ti,ab,kw OR LNS:ti,ab,kw
#4	randomly:ti,ab,kw OR randomized:ti,ab,kw OR RCT:ti,ab,kw OR
	trials:ti,ab,kw OR cohort:ti,ab,kw OR longitudinal:ti,ab,kw OR
	prospective:ti,ab,kw OR survival:ti,ab,kw

#5	#1 AND #2 AND #3 AND #4

4. Web of Science

Number	Search terms
#1	TS=(Non-Small-Cell OR Non-Small-Cell Lung Carcinomas OR Non-
	Small Cell Lung Cancer OR Non-Small-Cell Lung Carcinoma OR Non-
	Small Cell Lung Carcinoma OR Non-Small Cell Lung OR Non-Small Cell
	Lung Cancer OR Lung Neoplasms OR Pulmonary Neoplasms OR Lung
	Neoplasm OR Pulmonary Neoplasm OR Lung Cancer OR Lung Cancers
	OR Pulmonary Cancer OR Pulmonary Cancers OR Cancer of the Lung
	OR Cancer of Lung OR Non-Small-Cell Lung OR Lung Carcinoma OR
	Non-Small-Cell OR Lung Carcinomas OR NSCLC)
#2	TS=(Surgical Procedures OR Operative OR surgery OR surgery OR
	surgical OR operative OR postoperative)
#3	TS=(lymphadenectomy OR lymphadenectomy OR complete mediastinal
	lymphadenectomy OR mediastinal lymph node excision OR lobe-specific
	lymph node dissection OR mediastinal lymph node dissection OR
	mediastinal lymph node sampling OR lymph node dissection OR lymph
	node OR dissect OR sample OR selective mediastinal lymphadenectomy
	OR systematic lymph node dissection OR selective lymph node dissection
	OR LND OR LNS)
#4	TS=(randomly OR randomized OR RCT OR trials OR cohort OR
	longitudinal OR prospective OR survival)
#5	#1 AND #2 AND #3 AND #4

5. China National Knowledge Infrastructure (CNKI) (Chinese)

Search terms
(主题:"非小细胞肺癌" or "肺癌") and (主题:"淋巴结清扫方式" or "系统性
淋巴结清扫" or "选择性淋巴结清扫" or "叶特异性淋巴结清扫" or "纵膈淋巴
结清扫" or "纵膈淋巴结采样") and (全部: "随机对照试验")

6. WANFANG DATA (Chinese)

Search terms
(主题:"非小细胞肺癌" or "肺癌") and (主题:"淋巴结清扫方式" or "系统性
淋巴结清扫" or "选择性淋巴结清扫" or "叶特异性淋巴结清扫" or "纵膈淋巴
结清扫"or"纵膈淋巴结采样") and (全部:"随机对照试验")
Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies

7. Chinese biomedical literature service system (Sinomed) (Chinese)

Search terms ("非小细胞肺癌" [常用字段:智能] OR "肺癌" [常用字段:智能]) AND ("肺癌"[常 用字段:智能]) AND ("随机对照试验"[常用字段:智能]) AND ("淋巴结清扫方式 "[全部字段:智能] OR "系统性淋巴结清扫"[全部字段:智能]OR "选择性淋巴结 清扫"[全部字段:智能] OR "叶特异性淋巴结清扫"[全部字段:智能] OR "纵膈淋 巴结采样"[全部字段:智能])

8. VIP database (Chinese)

(主题:"非小细胞肺癌" or "肺癌") and (主题:"淋巴结清扫方式" or "系统性淋巴结清扫" or "选择性淋巴结清扫" or "叶特异性淋巴结清扫" or "纵膈淋巴
淋巴结清扫" or "选择性淋巴结清扫" or "叶特异性淋巴结清扫" or "纵膈淋巴
结何扫 Or 纵膈淋口结术杆) and (主部: 随机对照试验)

First author	
Country, year	
Sample size (males/females)	
Median age, y (range)	
Design	
Include or exclude	
Reason(s) for exclusion	
Follow-up (mean and range) (months)	
Tumor location	
Tumor size(cm)	
Tumor stage	
Surgery procedure	
Adjuvant treatment	
Primary outcomes:	
1. Overall recurrence rate	
2. Local recurrence rate (ipsilateral	
lung, ipsilateral pleura, trachea, etc.)	
3. Distant metastasis rate (contralateral	
lung, contralateral pleura, bone, liver, etc.)	
Second outcomes:	
1. Regional recurrence rate	
2. Lymph node metastasis rate	

PRISMA-P (Pre address in a syste	ferred emati	ا Reporting Items for Systematic review and Meta-Analysis Protocols) 2015 caecy c review protocol*	items to
Section and topic	Item No	Checklist item	Reported or Page #
ADMINISTRATIVI	E INF(DRMATION	0
Title:		at the second seco	
Identification	1a	Identify the report as a protocol of a systematic review	P1
Update	1b	If the protocol is for an update of a previous systematic review, identify as such	N/A
Registration	2	If registered, provide the name of the registry (such as PROSPERO) and registration number	P2
Authors:			
Contact	3a	Provide name, institutional affiliation, e-mail address of all protocol authors; provide physical mathematical difference of corresponding author	P1
Contributions	3b	Describe contributions of protocol authors and identify the guarantor of the review	P10
Amendments	4	If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments	N/A
Support:			
Sources	5a	Indicate sources of financial or other support for the review	N/A
Sponsor	5b	Provide name for the review funder and/or sponsor	N/A
Role of sponsor or funder	5c	Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol	N/A
INTRODUCTION			
Rationale	6	Describe the rationale for the review in the context of what is already known	P3-4
Objectives	7	Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO)	P4-5
METHODS		gies	
Eligibility criteria	8	Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as years considered, language, publication status) to be used as criteria for eligibility for the review	P4-5
Information sources	9	Describe all intended information sources (such as electronic databases, contact with study authors, trail registers or other grey literature sources) with planned dates of coverage	P5
Search strategy	10	Present draft of search strategy to be used for at least one electronic database, including planned limit such that it could be repeated	P5

25			BMJ Open by copen	
			2024-08 /right, in	
;	Study records:			
	Data management	11a	Describe the mechanism(s) that will be used to manage records and data throughout the review $ding f$	P6
	Selection process	11b	State the process that will be used for selecting studies (such as two independent reviewers) through each phase of the review (that is, screening, eligibility and inclusion in meta-analysis)	P6
	Data collection process	11c	Describe planned method of extracting data from reports (such as piloting forms, done independent in duplicate), any processes for obtaining and confirming data from investigators	P6
]	Data items	12	List and define all variables for which data will be sought (such as PICO items, funding sources) any pre-planned data assumptions and simplifications	P6
- (1	Outcomes and prioritization	13	List and define all outcomes for which data will be sought, including prioritization of main and a definitional outcomes, with rationale	P5
<u> </u> 	Risk of bias in individual studies	14	Describe anticipated methods for assessing risk of bias of individual studies, including whether the base of the outcome or study level, or both; state how this information will be used in data synthesis	P6-7
]	Data synthesis	15a	Describe criteria under which study data will be quantitatively synthesised	P7-8
		15b	If data are appropriate for quantitative synthesis, describe planned summary measures, methods of combining data from studies, including any planned exploration of consistency (such as I ² , Kendal's s)	P7-8
		15c	Describe any proposed additional analyses (such as sensitivity or subgroup analyses, meta-regression)	P8-9
		15d	If quantitative synthesis is not appropriate, describe the type of summary planned	P8
]	Meta-bias(es)	16	Specify any planned assessment of meta-bias(es) (such as publication bias across studies, selective reporting within studies)	P8
	Confidence in cumulative evidence	17	Describe how the strength of the body of evidence will be assessed (such as GRADE)	Р9
]	* It is strongly recom clarification on the it PRISMA-P Group a <i>From: Shamseer L, M</i>	imend tems nd is o toher 1	led that this checklist be read in conjunction with the PRISMA-P Explanation and Elaboratign (offer when available) for im Amendments to a review protocol should be tracked and dated. The copyright for PRISMA-P. (including checklist) is held distributed under a Creative Commons Attribution Licence 4.0.	portant by the c review and
j	meta-analysis protoco	ols (PR	RISMA-P) 2015: elaboration and explanation. BMJ. 2015 Jan 2;349(jan02 1):g7647.	
			Ce	
			Slici	
			ee	
			¥	
			For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	